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ANEMIA IN RHEUMATOID ARTHRITIS: A REVIEW OF P~IS, DIACmSIS 
AND TREMMENT 
I . I INTRODUCTION 
Anemia frequently is a concomitant feature in chronic disease. It 
is often related to the underlying disease like in chronic renal 
failure, in which anemia develops by means of a decreased 
erythropoietin production. Other examples are gastrointestinal 
bleeding caused by a malignant, infectious or inflammatory process, 
hemolysis in inflammatory disorders and malignancy, malignant bone 
marrow infiltration and the various causes of (chronic) disease 
associated with hematuria, menorrhagia and hemolysis. Anemia can also 
be an indirect complication of the underlying disease, e.g. by means 
of poor nutrition or toxic side effects of drug therapy. 
Apart from these causes a specific type of anemia is associated 
with chronic infection, inflammation, malignancy and autoinnnune 
disorders (Table 1) termed the anemia of chronic disease (ACD). 
Cartwright did extensive research on the subject and defined the 
following criteria necessary for the diagnosis of ACD [1,2,3]: 1. 
decreased serum iron, 2. normal or decreased total iron binding 
capacity (TIBC), 3. decrease in iron saturation of transferrin, 4. 
decreased number of sideroblasts and increased stainable iron content 
in bone marrow. 
The anemia develops slowly and nonprogressively within the first 
month of the underlying disease and its severity is to some extent 
correlated with disease activity [3]. After one month's duration of 
the underlying disorder the hemoglobin (Hb) level is constant and 
independent of disease duration. The Hb rarely reaches a level below 
70% of normal in uncomplicated cases. Generally the cellular indices 
remain normal, but mean corpuscular hemoglobin (MCH) and mean 
corpuscular volume (MCV) can be low, even without iron deficiency [4]. 
The reticulocyte count is low for the degree of anemia. 
ACD also occurs frequently in patients with rheumatoid arthritis 
(RA) [5,6]. In general it is not different fromACD associated with 
other disorders (Table 1) and it develops in most patients with RA of 
a certain disease activity. In active RA, however, concomitant iron 
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* TABLE I Diseases associated with ACD 
AUTOIMMUNE DISORDERS 
RHEUMATOID ARTHRITIS 
SYSTEMIC LUPUS ERYTHEMATOSUS 
POLYMYOSITIS & DERMATOMYOSITIS 
SCLERODERMA 
VASCULITIS 
NEOPLASIA 
SOLID TUMORS 
M. HODGKIN 
NON-HODGKIN LYMPHOMAS 
* Fitting Cartwright's c:rite:ria; :ref. 
mentioned in the text a:re excluded 
CHRONIC INFECTIONS 
FUNGAL 
BACTERIAL 
endocarditis 
osteomyelitis 
pyelonephritis 
decubitus 
abcesses 
tuberculosis 
CHRONIC INFLAMMATORY DISORDERS 
SARCOIDOSIS 
M. CROHN 
ULCERATIVE COLITIS 
1-3. Other causes of anemia 
deficiency is :reported in a frequency of 30-70% of anemic subjects 
[7-12]. 
The purpose of this study is to summarize all data available f:rom 
the literature on pathogenesis, diagnosis and treatment of ACD and to 
formulate study aims fo:r this thesis as an effort to solve the many 
controversies which exist in this field. The following aspects of ACD 
will be dealt with: 
1.2 Pathogenesis 
1.3 Factors associated with other types of anemia than ACD in RA 
1.4 Factors associated with ACD in RA 
1.4.1 i:ron absorption 
1.4.2 mononuclear phagocyte system 
1.4.3 fe:r:ritin and lactofe:r:rin 
1.4.4 ineffective erythropoiesis 
1.4.5 mediators of erythropoiesis 
1.4.6 hemolysis and :red cell life span 
1.4.7 erythropoietin 
1.4.8 erythroid progenitor cells 
1.5 Functional aspects of ACD 
1. 6 Diagnosis 
1. 7 Treatment 
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1. 2 PAlliOGENES1S 
In RA many causes of anemia can be present apart from ACD. It can 
be the result from side effects of drugs or other secondary phenomena 
associated with RA. Some specific causes of other types of anemia tend 
to occur more frequently in RA than in a control population. The 
pathogenesis of these types of anemia is clearly different from ACD. 
Factors associated with ACD are a disturbed iron metabolism, an 
ineffective or inhibition of erythropoiesis, hemolysis, leucocyte 
endogenous mediators and decreased levels or decreased responsiveness 
to erythropoietin. 
Most studies on the pathogenesis of ACD have been carried out in 
RA patients, so that some of the pathogenetic factors may be more 
specific for ACD in RA than for ACD as a complication of other chronic 
diseases. 
1. 3 FACTORS ASSOCIATED Willi OTHER TYPES OF ANEMIA THAN ACD IN RA 
Gastrointestinal blood loss, occult or overt, may be seen in a 
higher frequency due to antirheumatic drugs like NSAIDs [ 13] and 
corticosteroids [14,15]. The increased ulcer prevalence in RA may be 
caused by an increased permeability of gastric mucosa for hydrogen 
ions [16]. 
Anemia in RA can also be the result of myelotoxic effects of gold, 
including aplastic anemia, [17,18] penicillamin [19] and cytostatic 
drugs [20]. 
Autoinmrune phenomena can occur in RA leading to destruction of 
erythrocytes or thrombocytes (with consequent bleeding tendency 
sometimes) [21]. Cases of pure red cell aplasia have been described in 
the course of RA [22]. 
Another contributing factor may be an increased plasma volume in 
RA, especially among women [23], and salt retention due to asp~r~n 
[23] which causes hemodilution with a slight anemia as a consequence. 
A number of vitamin deficiencies are found in patients with RA. 
Controversy exists about the occurrence of vitamin B12 deficiency. 
Bieder [24] found an increased frequency of pernicious anemia in RA, 
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but this was not confirmed by Ghazi [25]. Defective B12 resorption is 
only of clinical importance in a minority of cases, although gastric 
antibodies and gastric mucosal atrophy occur in a higher than normal 
frequency in RA [26]. 
Folic acid deficiency is also reported to be more frequent in RA 
[27], although megaloblastic changes are rare and possibly masked by 
other deficiencies [28]. Anorexia and increased utilization by 
proliferating synovial cells may be causes of folic acid deficiency 
[27,29]. 
An~mic RA patients are often vitamin C deficient, especially when 
using aspirin [30]. It is suggested that this deficiency might inhibit 
iron release from the mononuclear phagocyte system [31], resulting in 
hemosiderosis [32]. No clinical features of vitamin C deficiency are 
seen in these RA patients, however. 
Copper-deficiency, known to inhibit erythropoiesis [33], is not 
encountered in RA patients, in fact it is often elevated [34]. 
Sometimes a decreased serum pyridoxin is found in RA without signs of 
sideroblastic anemia, however [35,36,37]. 
It is clear that in RA frequently more than one cause of anemia 
may be present simultaneously. This implies that studies examining one 
specific pathogenetic factor in anemia in RA should be interpreted 
with care. 
I. 4 FACTORS ASSOCIATED WI1H ACD IN RA 
1.4.1 Iron absorption (Table 2) 
It was found by Roberts et al. [38] that iron absorption in anemic 
RA patients was disturbed unless concomitant iron deficiency was 
present. Later findings showed that iron absorption in RA patients is 
not different from controls [39]. Weber et al. did extensive research 
in the field of absorption, retention and utilization of iron in RA 
patients [40]. RA patients and iron deficient controls were given oral 
radiolabeled 59Fe after which activity was measured in blood samples. 
It was found that mucosal uptake of iron in RA patients was the same 
as in controls but iron deficient RA patients had a lower uptake than 
- 20-
iron deficient patients without chronic disease. Mucosal transfer was 
lower in RA patients compared to controls and was higher when patients 
were iron deficient. No direct correlation was seen between disease 
activity and iron absorption. In another recent study [41], using the 
same method, it was shown that patients with active RA and anemia have 
an impaired iron absorption, whereas RA patients without anemia had 
normal iron absorption. Boddy [39] and Weber [40] found a lower rise 
of iron absorption in iron deficient RA patients compared to iron 
deficient patients without chronic disease, but Benn [41] showed that 
the rise was maximal. 
The cause of increased retention and diminished absorption of iron 
in active RA remains unclear. A decrease in circulating transferrin 
with less free binding sites and iron trapping by submucosal 
intestinal tissue macrophages [42] might reduce iron transport to bone 
marrow. These findings are present in RA and ACD but not in iron 
deficient patients without chronic disease and may thus play a role in 
pathogenesis of ACD. 
In our opinion two major factors underly the conflicting data 
presented in these studies. Although Cartwrights definition of ACD is 
quite clear it must be noted that iron deficient RA patients also have 
a certain level of disease activity. If iron is administered to them 
the mononuclear phagocyte system (MPS) will also tend to retain iron 
(see Table IIb) as it will in ACD. Therefore RA patients with iron 
deficiency can not fully be separated from those with ACD resulting in 
either masking of differences or conflicting data concerning iron 
absorption. Another problem is that iron samples taken from blood are 
the net result of iron absorption and utilization but also from 
retention and release by the MPS. If the gastrointestinal MPS retains 
iron it could be interpreted as decreased iron absorption, whereas 
iron is also extracted from blood and retained by the MPS. Therefore 
in active disease measuring iron absorption remains a difficult 
problem. Since in ACD -by definition- iron stores are increased we 
believe that a decreased iron absorption is rather the result of 
active RA than a cause of ACD or iron deficiency. 
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TABLE 2 Iron metabolism in ACD 
DEFECTIVE 
IRON ABSORPTION 
DEFECTIVE IRON RELEASE 
BY 
POSITIVE 
OBSERVATION 
* 38,40,41 
a) mononuclear phagocyte 
system 47,48,49,52 
61 b) ferritin 
c) lactoferrin 
INEFFECTIVE 
IRON TURNOVER 
66 
67,68,69,72 
ROLE IN 
ACD 
-- +--
++I? ? 
? 
? 
+ + + + 
NEGATIVE 
OBSERVATION 
39,41* 
11,50,51 
51 
70,71 
A positive observation means that the factor involved was present 
whereas a negative observation means that the factor was absent. 
(- = positive observation/no role in ACD; + = positive observation/ 
role in ACD; ? =doubtful). Numbers reflect references cited. 
* In this study a normal rise was found in iron deficiency whereas in 
ACD iron absorption was decreased 
1.4.2 The role of the mononuclear phagocyte system (MPS) (Table 2) 
Iron must be incorporated into erythroblasts for haemsynthesis and 
hence hemoglobin production. Generally, two ways exist for transport 
to the developing erythroblast. If intravenous iron dextran is 
administered it will be directly cleared by the MPS (formerly called 
reticuloendothelial system; RES) after which retention or liberation 
into the circulation takes place as transferrin bound iron being 
utilized by erythroblasts [43]. It is postulated that a certain amount 
of iron is transported from the MPS to bone marrow as ferritin 
(rhopheocytosis) but this plays a minor role [44]. The second and most 
important iron source for erythroblasts is transferrin bound iron 
released by the MPS after the breakdown of hemoglobin from the 
erythrocytes [45]. Agreement exists considering the fact that the 
first route, i.e., release of iron by MPS with iron dextran as a 
source is not disturbed in RA. Ferrokinetic studies with 59Fe labeled 
transferrin showed normal erythrocyte incorporation in patients with 
RA and anemia after intravenous radiolabeled iron [46], while the same 
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author saw a diminished reutilization of iron after administering 59Fe 
hemoglobin [47] which was confirmed by Beamish [48] who used a double 
isotope method; 55Fe labeled dextran Hb was applied for measuring iron 
reutilization and 59Fe transferrin for plasma iron utilization. Bennet 
[49] found that 59Fe labeled dextran in RA patients was readily taken 
up by liver MPS but little mobilization occurred from it, except in a 
patient with concomitant iron deficiency. Williams [50] found, in 
contrast, no differences in MPS iron release between RA patients with 
and without ACD as well as normal controls, using a method which 
measures the conversion from 59Fe dextran to 59Fe transferrin although 
an unphysiological high dose was given. Bentley et al. [51] using 59Fe 
hydroxide colloid as substrate, confirmed this in 7 out of 9 patients. 
Studies on MPS iron release show the same controversy as was met 
in those considering iron absorption. It is obvious that the problem 
of overlap between iron deficiency and ACD is a major problem. In our 
opinion these studies should be repeated. Iron deficient RA patients 
should be separated more clearly from those with ACD, not only using 
stainable bone marrow iron as a parameter, which is a semiquantitative 
scale, but also using serum ferritin which reflects iron stores [8]. 
Furthermore, the iron deficient RA patients should be suppleted after 
which iron release must be measured again. The same holds true for 
those with ACD before and after antirheumatic treatment. This approach 
will eventually establish defective MPS iron release as a possible 
specific pathogenetic factor in.ACD. 
1.4.3 The role of ferritin and lactoferrin (Table 2) 
It was formerly thought that apoferritin synthesis was regulated 
by the amount of nonstorage cellular iron [52], but Konijn and Hershko 
[53] found that ferritin synthesis preceded a fall in plasma iron 
after an immunologic stimulus like the injection of turpentine 
resulting in abcess formation. A larger proportion of iron entering 
the cell will be bound by apoferritin, the synthesis of which is 
augmented in inflammation [53], explaining the hypoferremia. Serum 
ferritin reflects tissue ferritin [54]. In acute infections the rise 
starts within 24-30 hours [55]. It probably reflects the acute phase 
reaction in inflammation [56]. 
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Both ferritin [57] and iron content [58] are elevated in synovial 
fluid from RA patients. Ferritin is probably able to stimulate local 
free radical damage in joints by forming hydroxyl radicals [59], 
caused by iron release from ferritin, initiated by o2-. The free 
radical damage might contribute to the persistence of the synovitis 
[60]. Macrophages in RA have increased affinity for iron and they are 
a major component of the synovial membrane while RA synovium might 
have an increased iron avidity [61]. It might therefore be possible 
that these factors and the increased storage iron bound to apoferritin 
result in a decreased iron availability for and incorporation into 
erythroblasts, suggesting a role in the pathogenesis of ACD. 
Lactoferrin is (like transferrin) an iron binding protein. It is 
mostly located within granules in neutrophilic leucocytes [62] and 
concentrations of it are high in inflammatory sites [63]. Lactoferrin 
release is mediated by leucocyte endogenous mediators [64]. Its 
affinity for iron is. higher than transferrin [65]. Lactoferrin and 
iron are taken up easily by macrophages [66]. The result can be 
hypoferremia and decreased iron availability for transport to 
erythroblasts. Hansen [11] however, found that serum level of 
lactoferrin in anemic RA patients is not different from controls. This 
does not exclude a role of extravascular lactoferrin in the genesis of 
hypoferremia and ACD in these patients. 
Iron trapping by the iron binding proteins ferritin and 
lactoferrin resulting in a decreased iron availability for bone marrow 
might be a contributive factor in the pathogenesis of ACD. 
As stated in paragraph 1.4.2. these measurements should be done 
both transversally (comparing nonanemics, iron deficient patients and 
patients with ACD) and longitudinally (before and after antirheumatic 
treatment). 
1.4.4 Ineffective erythropoiesis (Table 2) 
It was found by Samson et al. [67] that in a patient with RA and 
ACD ineffective erythropoiesis was increased and returned to normal 
after antirheumatic therapy. They used a method which assesses 
ineffective erythropoiesis by measuring production of labeled 
bilirubin coming from the breakdown of red cell precursors. This 
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finding was confirmed by others who found ineffective iron turnover 
(IIT) in 6 of 11 patients with RA and ACD, using a ferrokinetic study 
based on the disappearance curve of 59Fe labeled transferrin which 
reflects iron reflux from bone marrow into plasma [68]. In this manner 
iron incorporation into circulating red cells is called effective iron 
turnover (EIT). The sum of the two is total marrow iron turnover 
(MIT). This method was originally described by Rickets et al. [69]. It 
was shown in later studies, however, that IIT increase is in fact more 
specific for concomitant iron deficiency in ACD [70,71]. 
Another approach was to culture erythroblasts in vitro and measure 
the release of 59Fe haem from them. It was found that the release of 
59Fe haem was significantly higher in RA patients with ACD compared to 
nonanemic RA patients, while it decreased after antirheumatic drug 
treatment and a correlation existed between 59Fe haem release and 
disease activity [72]. 
IIT was supposed to be increased in ACD [67]. In other studies IIT 
turned out to be related to iron deficiency. This clearly demonstrates 
once again that in these studies patients' iron status should be 
properly defined. The in vitro studies measuring haem release from 
cultured erythroblasts point to a role of IIT in ACD. It could, 
however, also be argued that a higher percentage of erythroblasts die 
in vitro, resulting in increased haem release. We therefore think that 
a role of IIT in ACD can only be proven if patients are well defined 
and the methods sufficiently standardized. The 2 different approaches 
should be evaluated in the same patients before and after 
antirheumatic or -in case of iron deficiency- iron treatment. 
1.4.5 Mediators of erythropoiesis (Table 3) 
Many mediators have been described with both stimulatory and 
inhibitory effects on bone marrow cells. 
Acidic isoferritins were able to suppress in vitro growth of 
granulocyte and macrophage progenitor cells [73,74,75]. They were 
shown to be released from leukemic cells suggesting a role of bone 
marrow depression in leukemia. Their role in erythropoiesis and ACD is 
not yet fully established. 
Prostaglandins are important mediators of erythropoiesis. 
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Prostaglandin E1 (PGE1 ) stimulated erythroid colony growth but 
inhibited granulocyte and macrophage progenitor cells [76]. PGE2 
however, did not affect erythropoiesis in vitro [77]. Arachidonic acid 
metabolites in the lipoxygenase pathway are essential for erythroid 
colony growth which was confirmed by the observation that inhibitors 
of this pathway reduced erythropoiesis. Inhibitors of the 
cycle-oxygenase pathway in contrast (such as aspirin) did not affect 
erythropoiesis [78]. Indomethacine, a PG synthetase inhibitor, did not 
influence erythropoietin induced erythroid colony growth [77]. 
Considering these findings it is very hard to investigate the effects 
of NSAID's, commonly used in RA treatment, on erythropoiesis in vivo 
and in vitro in RA patients with ACD, because the effects are 
different and not fully restricted to one certain pathway. 
Serum interferon (IFN) gamma levels were elevated in aplastic 
anemia, whereas anti-IFN gamma addition in bone marrow cultures from 
these patients restored bone marrow cell growth [ 79] . IFN gamma 
suppressed erythroid colony growth [80] in pure red cell aplasia, 
whereas IFN alpha stimulated erythroid colony growth in myelodysplasia 
[81]. Peripheral blood lymphocytes were shown to produce· decreased 
amounts of IFN gamma in RA patients [ 82]. This suggests that IFN gamma 
might be of no pathogenetic importance in ACD in RA patients, although 
in this study [82] the authors did not examine parameters of 
erythropoiesis. 
It was found that a substance in sterile peritoneal exsudates in 
rabbits was able to cause fever. This was first called leucocyte 
pyrogen [83]. Later it was discovered that this substance was able to 
induce neutrophil release from bone marrow and synthesis of acute 
phase reactants like fibrinogen, ceruloplasmin,. c-reactive protein, 
haptoglobin and others [83,84]. Because of its various biologic 
activities it was then called leucocyte endogenous mediator (LEM). It 
was also found that it was presumably produced in macrophages and that 
it exerted activating effects on lymphocytes after which it was called 
interleukin-1 (IL-l) [85]. 
It is known to produce degranulatipn in leucocytes with release of 
lactoferrin as a consequence [64]. Serum iron remained low during 
daily injections of LEM; possibly it was trapped by lactoferrin [86], 
resulting in a lower iron availability for erythroblasts. 
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Theoretically it is possible that LEM inhibits erythropoietin 
production because it is known to inhibit the biosynthesis of various 
proteins [85,87]. It was shown that IL-l production by monocytes was 
higher in case of exacerbation of RA activity [88]. Schooley et al. 
[77] found that IL-l was able to suppress erythropoietin-stimulated 
erythroid colony growth in vitro in mice. This effect was seen in both 
anemic and nonanemic mice, although less pronounced in the latter. 
Maury et al. [ 89] also showed that IL-l inhibited erythroid colony 
growth while he saw that serum IL-l was lower in nonanemic than in 
anemic RA patients. It was concluded that IL-l could play a role in 
the pathogenesis of anemia in RA. Others however [ 90], found a lower 
monocyte IL-l production in peripheral blood from RA patients compared 
to controls, making its role in vivo in RA and ACD less certain. 
IL-2 production by T lymphocytes was shown to be inhibited by gold 
salts in vitro, the gold-concentration used being similar to the in 
vivo situation [91]. IL-2 was shown to reduce erythoid colony count 
[92]. In this way a possible direct or indirect role in the 
pathogenesis of ACD could be argued. However, IL-2 production by 
synovial cells with and without stimulation by phytohemagglutinin was 
the same in RA and control patients [ 93] , whereas in one study serum 
IL-2 inhibitor was increased in RA, suggesting decreased IL-2 activity 
[94] and in another it was decreased [95]. These contradictory 
findings do not support an unequivocal role in vivo of IL-2 in ACD in 
RA. 
IL-3 {multi-CSF) was shown to stimulate bone marrow cells to form 
myeloid colonies [96]. It potentiated the effects of G-CSF and GM-CSF 
in vitro. Erythroid colony growth was also stimulated by IL-3 addition 
to the marrow cultures [97]. It is not known whether this phenomenon 
might serve to counteract effects of other interleukins and prevent 
ACD in RA in vivo. 
IL-6 is another monokine with biological activities related to 
inflammatory responses [98,99]. IL-6 levels were elevated in synovial 
fluid of patients with RA [100]. It is able to stimulate erythroid 
colony growth especially in the presence of IL-3 [101,102], although 
others found no effects on erythroid colony growth [103]. For its 
possible stimulatory effects on erythropoiesis it might play a counter 
regulatory role to other interleukins in ACD. 
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It was shown that tumor necrosis factor (TNF) was able to induce 
resorption of proteoglycan and to inhibit proteoglycan synthesis in 
cartilage in vitro, suggesting a pathogenetic role in RA [104]. 
Goodman [ 105] found that both activated macrophages and TNF, one of 
their products were able to suppress erythroid colony growth. Lu also 
showed inhibitory effects of TNFcx. on erythropoiesis [76]. In another 
study it was shown that TNFcx. addition resulted in release of 
multipotential colony stimulating activity from fibroblasts [106] 
through which it might possibly counteract its direct suppressive 
effects on erythropoiesis in vivo. 
TABLE 3 Possible role of mediators of erythropoiesis in ACD and their 
effects on erythropoiesis 
MEDIATORS OF ERYTHROPOIESIS 
ERYTHROPOIESIS INCREASE DECREASE 
* * * ACIDIC ISOFERRITIN 73 ,74 ,75 
PROSTAGLANDIN 76,78 
INTERFERON ALPHA 81 
INTERFERON GAMMA 79,80 
INTERLEUKIN-1 77,89 
INTERLEUKIN-2 
96**,97 
92 
INTERLEUKIN-3 
INTERLEUKIN-6 101,102 
TNF ALPHA 106 76,105 
NO EFFECT 
77 
93 
103 
ROLE IN 
ACD 
? 
? 
+/'? 
++/'? 
+/-
?/'? 
-/'? 
++/-
(- = positive observation/no role in ACD; + = positive/ role in ACD; 
? -doubtful). NUmbers reflect references cited. 
* decrease in granulocyte and macrophage progenitor cells. 
** stimulation of myeloid colonies. 
All studies described above deal with in vitro effects of 
mediators of erythropoiesis. In the various studies cultures from 
various subsets of patients are examined, e.g., normals, patients with 
RA or leukemia. Results from these studies often are difficult to 
compare. The inhibitory effects of IL-l and TNF on bone marrow 
precursors seem to be consistent. Although some biological effects of 
these cytokines have been described in the clinical situations it is 
not yet proven whether the inhibitory effects on erythropoiesis also 
are present in vivo. Elevated serum levels reflect disease activity 
but do not prove a role in ACD. We believe the best approach to prove 
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in vivo effects is to measure monocytic cytokine production from 
inflammatory joints and bone marrow before and after antirheumatic 
treatment and to correlate these differences with changes in Hb and 
erythroid colony counts. Another theoretical - method would be to 
administer interleukins, prostaglandins or interferons, and antibodies 
to these substances to patients and follow erythropoiesis. The effects 
of antirheumatic treatment modalities on bone marrow cells are 
difficult to avoid but should be kept as constant as possible in both 
transversal and longitudinal studies. 
1.4.6 Hemolysis and red cell life span 
Many authors found a reduced red cell life span in ACD ranging 
from 81-90 days in anemic RA patients and 98-114 days in controls 
[68,107]. It is possibly explained by increased phagocytic capacity of 
macrophages [108] resulting in a higher clearance rate of erythrocytes 
[2,3,109]. 
Since fever may result in erythrocyte damage [110], especially in 
older ones, this might also contribute to a decreased red cell life 
span. Shortening of erythrocyte survival in these studies is only 
moderate and shows considerable overlap with controls, while fever is 
not very frequent in RA and is certainly not specific for anemic RA 
patients. The absence of an increased reticulocytosis as a reaction to 
hemolysis further points to other more important factors involved. 
1.4.7 Erythropoietin 
Generally in patients with normal renal function serum 
erythropoietin rises when anemia or a hypoxic stimulus is present 
[111,112]. Erythropoietin is reported to stimulate the rate limiting 
enzym in haemsynthesis, delta amino laevulinic acid synthetase 
(ALA-5) . The rate of haemsynthesis was found to be lower in anemia of 
chronic infection [113]. Failure of ALA synthetase rise in response to 
anemia, pointing to a marrow defect or an inadequate erythropoietin 
response, was also suggested [114]. Some authors found erythropoietin 
levels to be lower than expected for the degree of anemia in RA 
[115,116]. Cotes, using a sensitive radioimmunoassay, found 
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erythropoietin levels within the normal range, which were independent 
of the type of anemia [117], although he also showed that some RA 
patients did have inadequate erythropoietin levels. The same 
controversy was present in anemia associated with malignancy and 
infection [118]. Zucker [119] suggested rather a decreased bone marrow 
responsiveness to erythropoietin than a decreased level in the case of 
malignancy. More recent studies are still controversial. Erslev 
[112,120] found higher levels of erythropoietin in anemic patients 
irrespective of the cause which is in agreement with a study by 
Birgegard [121], who found a correlation between hemoglobin, ESR and 
erythropoietin level. In RA patients it was suggested that disease 
activity dictates Hb level which in turn causes a rise in 
erythropoietin level. This is in contrast with Baer, who saw lower 
erythropoietin levels in anemic RA patients compared to other anemic 
patients [122]. Since in most studies a negative correlation is found 
between Hb and parameters of disease activity it could be that Epo 
production rises when RA activity declines resulting in a Hb increase. 
From the above data we conclude that the role of a decreased Epo 
responsiveness in ACD is not unlikely in ACD but it could·be a side 
phenomenon of increased RA disease activity. Its specific role can 
only be proven when a Hb rise follows administration of exogenous 
recombinant DNA erythropoietin while leaving antirheumatic treatment 
unchanged. 
1.4.8 Erythroid progenitor cells 
Since the discovery of methods for culturing erythroid progenitor 
cells in methylcellulose as a medium, much research has been carried 
out to establish a possible mechanism at stem cell level in the 
pathogenesis of ACD. Two types of erythroid cells can be cultured, 
colony forming units (CFUe) and burst forming units (B~e). Growth of 
these cell lines generally are stimulated by T cells and macrophages 
[123]. It was found that CFUe growth in the presence of fungal 
infection [124] and cancer cells [119], was inhibited in experimental 
animals. The same inhibition occurred in mice after abcess induction 
by turpentine [125]. In normal mice CFUe growth was stimulated by 
erythropoietin, while in mice with an abcess erythropoietin was much 
- 30 -
less able to stimulate growth. 
In RA patients with and without anemia Reid found CFUe and BFUe 
growth was not different [126]. Depletion of macrophages resulted in 
decreased growth in both groups while readdition restored growth. 
Harvey et al. [127] found that mean BFUe colony number from peripheral 
blood of anemic RA patients was lower than nonanemic RA and control 
patients, but this was not significant. They also found decreased 
growth after T cell depletion in all groups. Prouse et al. [128] also 
reported stimulating effects of T cells on BFUe growth in both normal 
volunteers and anemic RA patients. Other authors in contrast reported 
that peripheral T cells from anemic RA patients inhibited CFUe growth 
in normal subjects [129]. This was not the case when T cells of normal 
subjects were used. Autologous serum inhibited BFUe growth in anemic 
RA patients as well as in nonanemic RA patients. In another study, 
however, only serum from 2 of 7 anemic RA patients inhibited 
erythropoiesis [129]. Serum from nonanemic RA patients stimulated BFUe 
growth [126]. Others found an inverse relationship between BFU colony 
numbers and serum IgM titer and rheumatoid factor [127]. 
Data from studies using in vitro experiments with erythroblasts 
should be interpreted cautiously. In these studies erythroblasts are 
cultured in media consisting of other marrow cells and serum. These 
factors might either stimulate or inhibit erythroid colony growth for 
instance by production of certain. interleukins in the cultures. The 
findings can not be extrapolated to the clinical situation. The 
finding of a negative correlation of IgM rheumatoid factor level and 
BFUe count [127] therefore is coincidental in our opinion. A possible 
connection could be that bone marrow cultures of RA patients with ACD 
produce for instance more IL-l or TNF than in those of nonanemic RA 
patients resulting in a reduction of erythroid colony growth (see 
under section: Mediators of erythropoiesis). So far, data lack to 
prove this assumption. 
I. 5 FUNCTIONAL ASPECTS OF ACD 
In most of the above theories the development of ACD could be 
explained by a decreased erythropoiesis. A decreased iron availability 
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is one of them. The question arises what purpose is served by this 
phenomenon. In infection it is known that hypoferremia might be a 
protective factor because most micro-organisms need iron for their 
metabolism [130,131,132]. Lactoferrin and transferrin inhibit 
bacterial growth and this inhibition is decreased when iron is added 
to saturate these proteins [133]. Hershko [134] recently found in a 
review of studies on iron deficiency and infection beneficial effects 
of iron deficiency, although not always consistent. Andrews saw 
reduction in joint inflammation in Wistar rats when they were made 
iron deficient, although this was not seen in a change in serological 
parameters [135]. It is also stated that a high level of synovial iron 
anticipates poor prognosis [136] in RA and arthropathy can be a 
manifestation of iron overload without arthritic disease [137]. It is 
also claimed that iron treatment may be deleterious in RA patients 
because it might worsen the synovitis [138,139]. 
It may be concluded that hypoferremia plays a protective role in 
RA. The finding of a high prevalence of iron deficiency among RA 
patients [11], impaired iron absorption in active RA [41], a possibly 
diminished MPS iron release [47,48] and trapping of iron by ferritin 
and lactoferrin [53,63] might point to a mechanism which prevents iron 
deposition in joints to some extent. Whether the anemia in ACD as such 
has beneficial effects is not known. 
1.6 DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS 
The suspicion of the presence of ACD rises when the patient has a 
chronic disease, reflected by clinical and laboratory signs, and 
anemia, when no other apparent causes of anemia are present. In the 
case of RA serological markers of disease activity are erythrocyte 
sedimentation rate, c-reactive protein, C1q binding assay and Rose 
titer. Correlation exists between disease activity and presence and 
severity of ACD [3,121]. If hypoferremia, decrease in iron saturation 
of transferrin capacity, normal to decreased serum transferrin are 
also present (Cartwright criteria; [1,2,3]) together with a relative 
low reticulocyte count the diagnosis seems probable. Generally the 
anemia is normochromic normocytic [1,2,3,4] but hypochromasia and 
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microcytosis may be present without concomitant iron deficiency [4], 
especially in juvenile rheumatoid arthritis [140]. 
The diagnosis of ACD is made by exclusion since many other causes 
may be present in RA. Gastrointestinal blood loss, adverse reactions 
of antirheumatic drugs, autoimmune phenomena and vitamin deficiencies, 
which are more frequent in RA than in a control population as was 
discussed previously, should be ruled out. 
The main problem in differential diagnosis of ACD in RA is the 
presence of concomitant iron deficiency. Iron deficiency is reported 
in frequencies from 30 to 70% among anemic RA patients [7-12]. The 
most reliable par?ffieter for the detection of iron deficiency is 
stainable iron content in a bone marrow aspirate [141,142]. No or 
scarce amounts of stainable iron point to iron deficiency while an 
increased amount of it fits the concept of ACD. Because of the high 
prevalence of anemia and iron deficiency in RAbone marrow aspiration 
is not a practical approach. Therefore, a number of studies were 
performed to correlate serological and erythrocyte parameters with 
stainable bone marrow iron content. Simple iron deficiency in patients 
without chronic disease is easily recognized by: microcytosis, 
hypochromasia, low serum iron, high transferrin, a low serum iron to 
transferrin ratio and a low serum ferritin [143,144]. In RA, if iron 
deficiency is present, it generally coexists with ACD. Although in ACD 
all these parameters can be similar to what is found in iron 
deficiency although transferrin generally is lower and ferritin higher 
[1,2,3,4] it was shown that MCV and MCHC can be reduced in 32 and 49% 
of patients respectively in ACD without iron deficiency [4]. In 
juvenile rheumatoid arthritis and anemia MCV can be as low as 60 fl 
without iron deficiency [140]. In other studies, however, MCV at a 
level of 80 fl turned out to be the most specific and predictive 
parameter for the detection of iron deficiency [11]. MCH is not a 
valid marker of iron deficiency [11]. Recent work shows that red blood 
cell distribution width (ROW) varies with MCV and Hb but no 
significant difference exists between ACD with and without iron 
deficiency [145]. ROW apparently correlates more with the severity 
than the type of anemia. 
Serum iron in ACD does not correlate with body iron stores in 
anemic RA patients [11] and anemic geriatric patients [146]. 
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Serum transferrin levels generally are lower in ACD and for the 
detection of iron deficiency it is not a valid test [11]. 
Serum ferritin, however, correlates best with stainable bone 
marrow iron content [11,146,147] in RA patients. Different cut off 
points (c.o.p) are used for the diagnosis of iron deficiency in RA. 
Patterson [1461 showed that 45 pg/1 was optimal, Hansen [11] and 
Rajapakse [9] used 60 pg/1. In healthy individuals lower limit is 12 
pg/l. 
Erythrocyte-ferritin was shown to be a reliable parameter for the 
detection of iron deficiency in patients without chronic disease [148] 
but in the evaluation of anemia in RA it was not very useful [149]. 
The usual findings of iron deficiency in peripheral blood are also 
present in anemic iron deficient RA patients. For its detection 
erythrocyte and serological parameters should be adapted because 
coexistent ACD tends to change these parameters in an opposite 
direction than iron deficiency does. 
Age might be a contributive factor. Mean age is frequently above 
60 years in RA patients [11] and it is known that in elderly people 
unexplained anemia is more common [150], possibly due to a defect in 
hematopoiesis in aging [151]. 
It is clear that the diagnosis of ACD can only be made by 
exclusion of other types of anemia. As was shown in other paragraphs 
other causes of anemia frequently coexist with ACD. Coexistent iron 
deficiency remains the most important differential problem. A bone 
marrow aspiration for iron status remains the golden standard. We 
conclude that in all anemic RA patients iron status should be examined 
to direct a diagnostic work-up of iron deficiency as well as serum B12 
and folic acid whereas hemolysis and toxic effects of drugs should be 
ruled out as well. 
1 . 7. TREATMENT 
ACD generally is a mild and n~nprogressive type of anemia 
resulting in a hemoglobin level rarely less than 70% of normal. 
Treatment, however, is only absolutely indicated when coexistent 
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angina pectoris, heart failure or respiratory failure is present. A 
major operation might also be an indication. Relative indications are 
pregnancy, reduction of exercise tolerance, fatigue, palpitations, 
dizziness, tinnitus and headache. Depending on severity of anemia and 
the underlying disease, it is to be decided whether blood transfusion 
or more longstanding therapy is needed. If other causes of anaemia are 
present they should be treated correspondingly. When antirheumatic 
drug toxicity is involved the drug must be withdrawn and the patient 
must be treated in a different way. 
Since there is some correlation between RA disease activity and 
severity of anemia [3,121], while nonanemic RA patients usually have a 
lower disease activity compared to anemic RA patients [2,3], the 
mainstay of management of the anemia is to treat the RA. Samson [ 67] 
showed that anemia and ineffective erythropoiesis was reverted after 
treatment of the RA with gold. It was shown that 3 months of 
antirheumatic treatment in patients with RA and ACD resulted in a 
significant Hb rise and decrease in disease activity, independent of 
treatment modality [121]. 
In the past ACD was treated succesfully with cobalt [152] but 
because of its toxicity this is not suitable for longterm treatment. 
A temporary rise in Hb and MCV may follow intravenous or 
intramuscular injection of high doses of iron [153,154]. After 
treatment Hb fell to initial values. Others reported that only anemic 
RA patients with iron deficiency respond to iron treatment [9,155]. If 
the clinical situation does not point to secondary causes of iron 
deficiency it is difficult to decide to treat anemic RA with iron 
without performing a bone marrow aspiration for assessment of 
stainable iron. As in the diagnosis of iron deficiency ferritin might 
be a predictor of iron responsiveness of the anemia [155]. RA disease 
activity declined during the course of iron treatment in these 
studies, which may be an important contributive factor in Hb rise. On 
the other hand it can be concluded that iron treatment in iron 
deficient RA patients is not harmful. Reddy [138] and Blake [139], 
however, 
parenteral 
found worsening of disease activity but they used high 
doses. As was discussed in a previous section iron 
indepent of its cause, might be protective in RA deficiency, 
[130,131]. 
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Based on the observations of the possible deleterious effects of 
iron on synovitis some authors evaluated the effect of iron chelators. 
In animal models it was shown that desferrioxamine, an iron chelator, 
stimulated the acute inflammatory reaction, but inhibited chronic 
inflammation in RA [156]. Andrews [157] showed that soft tissue 
swelling and bone erosions decreased in Wistar rats using 
desferrioxamine in a dose of 100 mgjkg. In human RA patients a dose 
from 2 to 3 gram daily resulted in many toxic side effects, although 
in some of the patients inflammation improved [158,159]. Later when a 
dose of 1 gram daily was used no apparent side effects were found 
while pain, morning stiffness and ESR decreased [160]. In these 
studies a Hb increase was reported after tWo weeks of treatment, while 
a single dose of 1 gram resulted in a Hb rise already in 1 week [161]. 
In another study [162] it was shown that in 5 patients with RA treated 
with desferrioxamine for 6 months no improvement in RA activity was 
seen while Hb and ferritin decreased significantly. Recently it was 
shown that desferrioxamine treatment also raises Hb in hemodialysis 
patients after 3 months of treatment [163]. In all studies Hb declines 
after cessation of treatment. It is postulated that iron chelating 
agents increase transferrin receptor expression in human erythroblasts 
[164,165]. 
Since desferrioxamine can only be administered parenterally it is 
worthwhile to evaluate the effects of new oral chelating agents on ACD 
in RA. They have shown to be effective in thalassemia, myelodysplastic 
syndromes and transfusional hemosiderosis [166,167]. The use of iron 
chelators may have the advantage of both reducing disease activity 
[156,157] and to correct the anemia [161] but results are few and 
short term. In patients treated with desferrioxamine for 6 months, 
however, a significant Hb and ferritin decrease was found [162]. 
Baseline ferritin in these patients was low, however, suggesting iron 
deficiency instead of ACD. Long-term studies are necessary to evaluate 
the effect of oral iron chelation therapy on erythropoiesis, RA 
activity and potential toxicity. 
Although the role of erythropoietin in the pathogenesis of ACD 
remains to be established, it will be interesting in both therapeutic 
and pathophysiologic point of view to treat anemic RA patients with 
erythropoietin. It was found earlier that hypoxic stimuli could 
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correct ACD in rats suggesting an erythropoietin effect [168,169]. 
Exogenenous recombinant DNA erythropoietin is effective in the 
treatment of anemia in end-stage renal insufficiency [170,171]. 
Recombinant technology will increase the availability of the hormone 
[172] and therefore other indications than renal insufficiency, like 
ACD, have to be investigated. 
I. 8 DISCUSSION AND SU'v.I\MRY 
ACD is a frequent complication of chronic disease. Most of the 
studies considering diagnosis and pathogenesis of ACD have been 
carried out in RA patients because of the high prevalence in and 
homogeneity of this patient group. This, however, limits extrapolation 
of certain features in ACD to other chronic diseases (Table 1) since 
they could be connected to RA as such. 
Within the RA group itself diversity exists as well. Many studies 
reviewed here lack proper definition considering their iron status. 
This may have an important impact on interpretation of results, 
especially in those studies examining altered iron metabolism in ACD. 
This is illustrated by the fact that features as decreased MPS iron 
release and ineffective iron turnover were originally thought to be 
specific for ACD, but later it was shown to be associated with iron 
deficiency as well. Nearly all these studies have been carried out 
transversally. It is therefore recommended in future studies 
considering iron absorption, MPS 
be performed in a longitudinal 
examined before and after iron 
iron release and IIT that they will 
fashion. These factors should be 
treatment in iron deficient RA 
patients. In ACD iron chelators should be administered before and 
after which the same parameters should be studied since the observed 
increased erythropoiesis after this way of treatment might be due to 
increased bone marrow iron availability through iron release from 
ferritin, lactoferrin and the MPS. In the third arm of such a study RA 
patients with either iron deficiency or ACD should be 
antirheumatically. The same model can be used to prove a 
treated 
role of 
decreased erythropoietin 
consistency as well. 
responsiveness, for 
Serum erythropoietin 
these studies lack 
and parameters of 
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erythropoiesis in RA and ACD should be measured before and after 
either antirheumatic or exogenous erythropoietin treatment. The 
performance of such studies demands great efforts of both patients and 
investigators, but it will definitely solve many controversies. 
Another problem frequently seen in studies cited here is the 
extrapolation of in vitro findings to the in vivo situation. This 
holds especially true for studies examining erythroid progenitor cells 
and effects of mediators of erythropoiesis. This was discussed in the 
respective sections. A possible approach -in case of determining 
effects of LEM- is to administer substances as prostaglandins, 
interferons or interleukins and their antibodies or antagonists to 
patients. Apart from ethical aspects the problem of in vitro phenomena 
remains, considering studies on in vitro erythropoiesis, unless one 
wishes to rely on simple parameters such as Hb, Ht and reticulocytes. 
Another solution, culturing without serum or monocytes in order to 
prevent interleukin production with intrinsic effects on in vitro 
erythropoiesis is under investigation. 
We reviewed studies on pathogenesis, diagnosis and treatment of ACD 
in RA. Many pathogenetical factors are not unlikely to play a part in 
ACD such as impaired MPS iron release, iron trapping by iron binding 
proteins (such as ferritin and lactoferrin), decreased erythropoietin 
responsiveness to the anemia, suppressive effects on erythropoiesis of 
interleukins especially IL-l and TNFa, although data from the studies 
cited are far from consistent. Factors as hemolysis and decreased red 
cell life span are of minor importance. Hypoferremia in ACD might play 
a protective role in RA since iron could worsen symptoms. Longitudinal 
studies might substantiate the value of the different pathogenetical 
factors but they are very hard to perform for practical reasons. 
Another problem remains the insufficient description of iron status in 
many studies making interpretation difficult. 
The diagnosis of ACD depends on exclusion and the main differential 
problem is the detection of coexistent iron deficiency. Treatment, 
rarely indicated, should be directed towards antirheumatic treatment. 
Specific treatment modalities such as (oral) iron chelators and 
exogenous erythropoietin have to be investigated for both 
pathogenetical and therapeutic reasons. 
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I. 9 AIMS OF THE SWDIES 
1.9.1 To assess the frequency of iron, vitamin B12 and folic acid 
deficiency in RA patients and to examine the effects of these 
deficiencies on certain diagnostic parameters in blood in 
comparison with non-anemic RA patients (Chapter 3). 
1.9.2 To characterize the difference between ACD and ACD complicated 
by iron deficiency in RA by means of simple erythrocyte and 
serological parameters in order to predict the presence of iron 
deficiency by these parameters without performing a bone marrow 
aspiration for stainable iron. 
1.9.3 To predict iron responsiveness of anemia in RA by means of 
simple erythrocyte and serological parameters and to evaluate 
whether iron treatment results in a serological increase of RA 
disease activity (Chapter 5). 
1.9.4 To examine whether iron uptake by and transferrin binding to 
erythroblasts is defective in RA patients with ACD (Chapter 6). 
1. 9. 5 To establish a potential . pathogenetic role of a decreased 
erythropoietin responsiveness to anemia in RA patients with ACD 
and to examine whether Epo responsiveness is higher among iron 
deficient RA patients (Chapter 7 part one and two). 
1.9.6 To evaluate whether iron release from iron stores by oral iron 
chelation in RA patients with ACD results in increased 
erythopoiesis and increased Epo responsiveness to anemia 
(Chapter 8). 
1.9.7 To determine a possible potential role of TNFa in determining 
ACD in RA patients (Chapter 9) • 
1.9.8 To investigate whether IL-6 is involved in ACD pathogenesis 
(Chapter 10). 
CHAPTER 2 
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PATIENI'S, MATERIALS AND METHODS 
2.1 PATIENTS 
All RA patients included fitted the revised criteria of the 
American Rheumatism Association (ARA) and gave informed consent before 
entering the study. All protocols have been accepted by the Medical 
Ethical Committee of the Department of Rheumatology of the Dr Daniel 
den Hoed Clinic. 
In some studies in this thesis overlap in patients occurred. 
Patients without B12 or folic acid deficiency from the study described 
in Chapter 3 were used in Chapter 4 and 5 as well. For the in vitro 
studies on erythroblasts (Chapter 6, 9 and 10) bone marrow from 39 
subjects were used. The bone marrows used in Chapter 6 and 10 
consisted of subdivisions of those described in Chapter 9. In Chapter 
7 part one the results were obtained from a subset of patients 
described in Chapter 3. In Chapter 7 part two and Chapter 8 part of 
the patients were also used in Chapter 6, 9 and 10, whereas a number 
of other subsets were also included. 
2. 2 ERYTHROCYTE PARAMETERS (reference values) 
Hemoglobin was measured by a modified cyanmethemoglobin colori-
metric analysis at 540 nm. (7.4-10.9 mmol/1). 
Reticulocyte count was assessed by vital staining with brilliant 
cresyl blue, expressed as a ratio of red cells (0/00). 
Mean corpuscular volume was calculated from hematocrite and number 
of erythrocytes (Ht/ery's). (80-96 fl). 
Mean co~puscula~ hemoglobin was calculated f~om hemoglobin and 
number of erythrocytes (Hb/ery's). (1600-2200 amol). 
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2. 3 PARAMETERS OF IRON STATUS (reference values) 
Serum iron was assessed by colorimetric analysis of a ferrous 
iron;ferene complex at 595 nm without deproteinization and with 
reduction by ascorbic acid (Instruchemie, Hilversum, The Netherlands). 
(14-30 pmol/1). 
Transferrin was determined with a Baker nephelometer 420 (Ablon 
Medical Systems, Leusden, The Netherlands). (44-80 pmol/1). 
Serum ferritin was measured by solid phase enzyme immunoassay 
(Ferrizyme, Abott Labs Chicago, USA). (20-150 pg/1). 
Erythrocyte-ferritin was assessed after centrifuging erythrocytes 
with removing of the buffy coat and supernatant. The sedimentated 
erythrocytes were resuspended with 166 mM NaCl. This washing procedure 
was repeated twice. The final red cell sediment was hemolyzed at 0° C 
after which the supernatant was tested for ferritin [1]. 
2. 4 VITAMIN B 12 AND FOLIC ACID ASSAY 
Vitamin B12 and folic acid were measured using a radioassay 
technique (Dualcount, Diagnostic Products Corp., Los Angeles, USA). 
Reference values vitamin B12: > 150 pmol/l and folic acid> 7 nmol/l). 
2.5 PARAMETERS OF DISEASE ACTIVITY (reference values) 
Erythrocyte sedimentation rate was determined using the Westergren 
method ( < 10 mm/h). 
c-reactive protein was measured by using radial immunodiffusion 
partigen plates (Behring Werke, Marburg, West-Germany) (< 6 mg/l). 
C1q binding assay was measured by a method originally described by 
Zubler et al. [2] ( < 7%). 
waaler Rose test was assessed usin~ sensitized sheep erythrocytes; 
a titre more than 1/32 was considered positive [3]. 
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2.6 GROWTH FACTORS 
2.6.1 Erythropoietin 
Erythropoietin in serum was assessed using a sandwich 
radioimmunoassay with monoclonal antibodies. In 30 healthy donors mean 
Epo was 14.5 ~ 4 U/1 which was considered normal (4]. In the other 
assay a sandwich assay with a double antibody assay was used [ 5] • In 
100 control sera mean Epo level was 22 + 4 U/ml). 
2.6.2 Tumor necrosis factor 
Serum TNF~was measured immunoradiometrically using monoclonal 
antibodies against distinct epitopes of TNF~ after coated tube 
separation. (s.a. IRE-Medgenix, Fleurus, Belgium) (reference value: 
6.3 pg/ml, range 5-8). 
2.6.3 Interleukin-6 
IL-6 in serum was measured in the B9 assay [ 6] . Serum was heated 
for 30 minutes at 56°C and a titration was added to 5000 B9 cells and 
compared with standard IL-6 preparation. After 3 days proliferation 
was measured by thymidine incorporation. 1 U/ml is a concentration 
that leads to half maximal proliferation. In 100 controls serum levels 
were less than 10 U/ml. 
2. 7 URINE I RON EXCRETION 
This was assessed using atomic absorption spectophotometry. 
2. 8 IRON ABSORPTION TEST 
Serum iron was measured after an overnight fast after which a 
tablet containing 105 mg elementary iron (FerogradumetR, Abbott BV, 
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Amstelveen, The Netherlands) was ingested. After 2 hours serum iron 
was measured again. 
The increase in serum iron expressed as q ratio of initial value 
was used as a parameter of iron absorption [7]. 
2. 9 BONE MARRCW ASP I RAT ION 
Bone marrow was aspirated after sternal or posterior iliac crest 
puncture. 
2.9.1 Stainable iron content 
Iron content was measured by staining with Perl's Prussian blue. 
A semiquantitative scale was used. 0 = no stainable iron, 0 - 1 
minimal to very small amount, 2 = slight small and patchy content and 
3 or more = increased stainable iron. On this scale patients with a 
stainable iron content of 0-1 were considered iron deficient [8,9]. 
2.9.2 Preparation of cell suspension 
Twenty ml bone marrow aspirate was collected in Hank's balanced 
salt solution (HBSS) with heparin diluted in HBSS and layered over a 
Ficoll gradient (1.077 g/cm2 ); Nycomed, Oslo). After centrifugation 
the mononuclear cells were harvested, washed twice in HBSS and 
resuspended in HBSS [10]. 
2.9.3 BFUe assay 
A cell suspension of 1.105 cells was added to a mixture of 
Iscove's modified Dulbecco's medium (IMDM), 0.40 ml with 2% 
methylcellulose, 0.30 ml fetal calf serum, 0.1 ml mixture (containing 
BSA, transferrin, lecithin, sodium selenite and 2-mercaptoethanol) 
after which 0.015 ml erythropoietin (1 U/1) was added. This volume was 
divided over 4 petridishes which ·were incubated at 37°C and 100% 
humidity in an environment of 
(BFUe; containing 50 or more 
(range 13-15) [10]. 
5% C0
2 
in air. 
cells) were 
Burst forming units 
counted after 14 days 
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2. 10 IRON INCORPORATION INTO AND TRANSFERRIN B!NDING TO ERYTHROBLASTS 
Iron incorporation into and transferrin binding to erythroblasts 
were measured as follows. Human transferrin (Behring Werke, Marburg, 
West Germany) was labelled with 125 I (Amersham Radiochemical Centre, 
UK) using Iodogen reagent (Pierce Chemicals, Rockford, IL) as 
catalyst. Another solution, containing a mixture of I 2 , Nai and 
Na125 I, was added slowly to the transferrin solution at 0°C. After 5 
hours of mixing at 4°C the surplus 
exchanging (Amberlite IR cl-) [11]. 
the purified transferrin solution 
of 1 2 5 I was separated by anion 
59 Fe(III) chloride was added to 
until 100% saturation [ 12] . A 
sodiumbicarbonate solution (5%) was also added as an anion-donor which 
is necessary for Fe(III) binding'to transferrin [13,14]. 
The cells were suspended in 10 ml of DMEM containing 0.5% BSA 
solution with addition of DNAse (30 mg/100 ml). Five nanomol 
transferrin was incubated per 15.106 nucleated cells for 2 hours at 
37°C. After 2, 30, 60 and 120 minutes duplicate samples of 0.5 ml were 
taken and stored in cold PBS. The samples were centrifugated at 1200 
rpm and 4°C during 7 minutes after which the supernatant was removed. 
Cells were then washed in PBS and centrifugated twice again after 
which activity of the cells was measured using a Packard-autogamma 
500.C. (13,14). I125 counts were corrected afterwards for 59 Fe 
spill-over (13% of 59 Fe counts). 
bound radioactivity -usually 
In all experiments non-specific cell 
less than 1 pmol/106 cells- was 
subtracted from the obtained experimental values. 
2.11 STATISTICS [15] 
2.11.1 Student-t-test 
This test was used for analysis of normally distributed data. 
The following formula was used: 
I s = 
[ 
(N1-l) .512 + (N2-l) .52 2 
N
1 
+ N1 -2 r 
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II ~(mean> - X2(mean) ~ t~ a.S. 
S = test value 
N1 N2 =number of observations in population 1 and 2 
S1 S2 =standard deviation population 1 and 2 
~ ~ = mean of observations in population 1 and 2 
The result of formula II should be more than zero. 
2.11.2 kfann Withney U test 
This test was used for analysis of non-parametric data. 
Observations of both populations were ordered from low to high. 
Each observation was given a ranknumber. The following formula 
was used: 
Sxminimal = M(M+1 ) Sxmaximal = M(M+2N+1) 
2 2 
M = sum of ranknumbers in population 1 
N = sum of ranknumbers in population 2 
Sx1 = test value for population 1 
If Sx is much larger or smaller than M(M+N+1)/2 it is concluded 
that the populations are different. 
2.11.3 Spearman's rank correlation test 
This test was used for correlation of data. Paired observations 
are given ranknumbers. The following formula was used: 
Rs = 1 -
(vl = ~ - sl l 
-1 < Rs < 1 
Rs 
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rank correlation coefficient 
ranknumber of observation la 
ranknumber of observation lb 
sum of differences in ranknumbers of paired observations 
(la and lB, 2a and 2b etc.) 
N = number of paired observations 
2.11.4 Wilcoxon sign-rank test 
This test was used for comparison of data from the same patients 
before and after treatment. 
2.11.5 Parameters of prediction of iron deficiency (chapter 4) 
and responsiveness of anemia to iron (chapter 5). 
Sensitivity was calculated as the ratio of patients with iron 
deficiency, who are positive for the variable and specificity was 
calculated as the ratio of patients without iron deficiency who 
are negative for the variable. Validity reflected the sum of all 
patients with iron deficiency and a positive variable and 
patients without iron deficiency and a negative variable 
expressed as a ratio of all patients. Predictive value 
represented the ratio of the number of patients with a positive 
variable who were iron deficient (see schedule below). 
positive variable 
negative variable 
sensitivity = A/A+B 
specificity = D/D+C 
* number of patients 
* I+ II 
(iron deficient) 
* III + IV 
(not iron deficient) 
validity = A+D/A+B+C+D 
predictive value = A/A+C 
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In the same way these parameters were used to predict a Hb rise in 
anemic RA patients who were treated with iron. 
positive variable 
negative variable 
sensitivity = A/A + B 
specificity = D/D + C 
* number of patients 
Hb rise Hb unchanged or 
decreased 
validity= A + D/A + B + C + D 
predictive value = A/A + C 

CHAPl'ER 3 
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DIAGIJSIS OF ANEMIA IN RA. THE INFLUENCE OF IRCN, VI22\MIN Bl2 AND 
FOLIC ACID DEFICimcY 00' BLOOD PARl\METERS IN PATIENI'S WITH ACD 
3 o I I NTR(X){}CT ION 
In patients with active RA anemia is frequently present [1,2]. 
Many types of anemia are associated with active RA. Vitamin B12 and 
folic acid deficiency are reported to be more prevalent among RA 
patients than controls [3,4]. Iron deficiency is found in a high 
frequency in RA [5,6]. Many RA patients with active disease also have 
ACD, originally described by Cartwright [7]. 
In patients with active RA more causes of anemia, associated with 
RA, may be present simultaneously. Studies on diagnosis and 
pathogenesis may thus be difficult to interpret. 
We therefore performed a study to assess the frequency of iron, 
vitamin B12, folic acid deficiency in RA patients and to examine the 
effects of these deficiencies on certain diagnostic parameters in 
blood in comparison with nonanemic RA patients. 
3 o 2 PATIENTS AND METHODS 
30201 Patients 
Thirty-six patients ( 5 males) with definite or classical 
rheumatoid arthritis were studied. Patients who were recently treated 
with iron, folic acid or vitamin Bl2 were excluded. Patients with a 
present or past ulcer history, hypermenorrhoe, hematuria, positive 
stools for occult blood, hemolysis or decreased creatinin clearance 
were also excluded. Overall disease duration was 7 years, 62% of the 
patients used longacting antirheumatic drugs while 82% was treated 
with nonsteroid anti-inflammatory drugs. Patients were divided into 3 
groups. Group I (n=ll) consisted of RA patients without anemia. Group 
II (n=l3) consisted of anemic and iron deficient RA patients and group 
III {n=12) consisted of anemic patients without iron deficiency; they 
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were considered as having ACD (grade 2 or more stainable bone marrow 
iron, see Chapter 2.9.1). In group I mean age was 54 years, in II 62 
and in III 65 years. The difference between I and III was not 
significant (p<0.20). No difference in disease duration and 
antirheumatic drugs used were found in three groups. 
3.2.2 Laboratory procedures 
The following parameters, described in Chapter 2, were assessed: 
Erythrocyte parameters: 
Hb, MCV, MCH, reticulocyte count. 
Iron status: 
serum iron, transferrin, ferritin. 
Vitamin B/2, folic acid. 
Parameters of disease activity: 
ESR, CRP, Clqba and Rose titre. 
Bone marrow was aspirated after sternal puncture in the anemic 
patients, after which stainable iron was determined. 
3. 3 RESULTS 
3.3.1 Relationship between cellular indices, stainable iron content, 
bone marrow iron content, serum vitamin B/2 and serum folic acid 
Iron deficiency occurred in 13/25 (52%) of anemic patients 
(Table 1). 
MCV was higher in I compared to II (p<0.002) and III (p<0.02) 
while in III it was higher than in II (p<0.05). 
MCH was higher in I compared to II (p<O.OOl) and III (p<O.OOl). 
It tended to be higher in III VS II (p<0.20). 
Reticulocytes were lower in I vs II (p<0.05) and III (p<0.02). 
The difference between II and III was not significant. 
Serum Bl2 was lower in group III compared to I and II but this 
was not significant (Table 1). In Table 2 it is shown that B12 
deficiency occurred most frequently in group III but differences were 
not significant. 
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TABLE I Erythrocyte parameters, iron status, serum B/2, serum folic 
acid and parameters of disease activity in group I 
(non-anemics), II (iron deficient patients) and III (ACD 
patients). Data are expressed as median with range. 
I 
(n=ll) 
Erythrocyte parameters 
Hb1 > (mmol/1) 
MCV (fl) 
MCH (amo1) 
reticu1ocytes 
(0/00) 
Iron status 
s-iron pmol/1 
8.1(7.6-8.4) 
. 91(80-97) 
1887(1630-2070) 
10(1-23) 
9(6-12) 
transferrin (pmol/1) 65(52-79) 
ferritin (.ug/1) 31(10-190) 
B12 and folic acid 
II 
(n=l3) 
6.0(4.2-6.7) 
78(71-100) 
1550(1310-2000) 
23(8-44) 
4(1-8) 
60(39-81) 
26(10-98) 
B12 (pmol/1) 213(117-557) 207(106-415) 
folic acid (nmol/1) 13.9(7.6-26.80 9.3(2.9-15.2) 
Disease activity 
ESR llUl1,lh 
CRP (mg/1) 
C1qba (%) 
Rose titer3 > 
(% positive) 
36(14-60) 
8(2-38) 
5(3-39) 
96(32-512) 
(54%) 
64(17-98) 
26(2-117) 
13(4-69) 
256(64-512) 
(62%) 
III 
(n=12) 
6.3(5.4-7.1) 
85(80-98) 
1647(1520-1950) 
32(13-69) 
5(1-10) 
51(39-65) 
90(45-221) 
165(38-319) 
9.0(5.0-13.9) 
90(49-128) 
36(6-122) 
29(7-100) 
96(32-1024) 
(83%) 
l) SI conversion: Hb in mmol/1 x 1.61 = g/dl. 
2
> Rise in serum iron expressed as a ratio from initial value, see 
) under "laboratory procedures". 1 3 Reciprocal titer of Rose test, patients with titers > /32 were 
considered positive. 
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TABLE 2 Effect of low serum B/2 (<!50 pmol/1) and low serum folic 
acid (< 7 nmol/1) on cellular indices in non-anemic patients 
(!), iron deficient patients (II) and ACD patients (Ill).* 
Serum B12 
low normal 
(<150 fmoljl) (>150 fmol/1) 
I 
Number (%) 3(30%) 
Hb (mmol/1) 8.1 
(7.7-8.4) 
MCV (fl) 93 
(90-97) 
MCH ( amol) 1973 
(1860-2150) 
II 
Number (%) 3(23%) 
Hb (mmol/l) 6. 5 
(6.4-6.6) 
MCV (fl) 88 
(82-100) 
MCH (amol) 1743 
III 
Number (%) 
Hb (mml/1) 
MCV (fl) 
MCH (amol) 
(1590-2000) 
4(36%) 
6.5 
(5.7-7.1) 
90 
(80-98) 
1757 
(1560-1950) 
7 
7.9 
(7.6-8.3) 
90 
(80-97) 
1839 
(1630-2010) 
10 
5.9 
(4.2-6.7) 
753 ) 
(60-87) 
14913 ) 
(1310-1730) 
7 
6.3 
(5.9-7.0) 
831 ) 
(80-90) 
15962 ) 
(1510-1780) 
serum folic acid 
low normal 
(<7 nmol/1) (~7 fmol/1) 
0 
4(31%) 
6.4 
(5.8-6.7) 
81 
(78-87) 
1560 
(1490-1640) 
1(9%) 
6.6 
83 
1590 
11 
8.1 
(7.6-8.4) 
91 
(80-97) 
1887 
(1630-2070) 
9 
5.9 
(4.2-6.7) 
77 
(60-100) 
1544 
(1310-2000) 
10 
6.4 
(5.4-6.7) 
85 
(80-98) 
1651 
(1510-1950) 
*In some patients serum B12 or folic,acid was not assessed. 
Data expressed as median and range 1 lp<0.10 2 lp<0.05 3 lp<0.02. 
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B12 deficiency was present in 10 patients, 8 of them (80%) had a 
normal Shilling test, 1 (10%) had gastric antibodies and 1 (10%) had 
undergone a gastrectomy. 
Hb was slightly lower in patients without B12 deficiency in 
group II (p<0.20). MCV was higher in patients with B12 deficiency 
compared to patients without B12 deficiency in group I (ns) II 
(p<0.02) and III (p<0.10). MCH was higher in B12 deficient patients in 
group I (p<0.20) II (p<0.02) and III (p<O.OS). No correlation existed 
between serum B12 level and MCV and MCH except for B12 and MCH in the 
anemic patients (r=-0.36, p<O.OS). 
Megaloblastic changes in bone marrow were present in 4 of 10 B12 
deficient patients (40%). 
Folic acid deficiency did not occur in the group of nonanemic 
patients (I). In group II it was found in 31% and in group III in 9% 
of patients (Table 2). No specific causes of folic acid were found. 
Table 1 shows that serum folic acid was lower in groups II and III 
compared to group I (p<0.02 for both). MCV and MCH were both higher in 
patients with folic acid deficiency in groups II and III but this was 
not significant. Megaloblastic changes in bone marrow were found in 1 
patient (2%). In patients with normal B12 a low folic acid occurred 
twice while in patients with normal folic acid a low Bl2 was found in 
3 patients. Folic acid correlated negatively with ESR (r=-0.49, 
p<O.OOS) and CRP (r=-0.43, p<0.01). 
one patient had a combination of iron, B12 and folic acid 
deficiency (Hb 6.6, MCV 83 and MCH 1590) while another had ACD with 
folic and B12 deficiency (Hb 5.7, MCV 87, MCH 1730). After correction 
of these findings the differences in cellular indices were slightly 
larger but significance level did not change. 
3.3.2 Relationship between stainable bone marrow iron content and 
parameters of iron status 
Serum iron was below normal (14 pmol/1) in all RA patients. It 
was lower in groups II and III compared to group I (p<0.002 for both) 
(Table 1). Difference between groups II and III was not significant. 
Transferrin did not differ in group I compared to II. It was 
lower in III compared to I (p<0.01) and II (p<O.OS). 
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Ferritin was lower in group II compared to group I (ns). It was 
higher in group III vs I (p<0.02) and II (p<0.002). A correlation was 
found between ferritin and ESR (r=0.49, p<0.05) as well as CRP 
(r=0.82, p<0.005 in group II and r=0.54, p<0.05 in III while in group 
I no correlation existed between ferritin and CRP). 
3.3.3 Parameters of disease activity (Table 1) 
ESR was lower in group I compared to II and III (p<0.002 for 
both). It was higher in III compared to II but this was not 
significant. 
CRP was lower in I than II (p<0.10) and III (p<0.02). The 
difference between II and III was not significant. 
C1qba was lower in I compared to II (p<0.10) and III (p<0.02). 
The difference between II and III was not significant. 
Rose titer was higher in II vs I (p<0.10). 
ESR correlated with Hb only in the ACD group (r=-0.52, p<0.05). 
CRP and C1qba did not correlate with Hb. 
3 . 4 DISCUSS ION AND SU'v..1144RY 
In this study we evaluated the importance of deficiencies of iron, 
B12 and folic acid in the differential diagnosis of anemia in RA. It 
was shown that iron deficiency occurred in 52% of anemic patients 
based on stainable iron content in bone marrow. In the nonanemic 
patients iron deficiency was not ruled out since no marrow aspiration 
was performed in this group. ACD (normal to increased stainable bone 
marrow iron) occurred in 48% of the anemic patients. 
Vitamin B12 deficiency occurred in about 30% of patients in all 3 
groups (serum B12 lower than 150 pmol/1) and folic acid deficiency 
(serum folic acid < 7 nrnol/1) was present in 21% of anemics (31% in 
group II and 9% in group III). 
MCV and MCH were found to be lower in the iron deficient patients 
compared to nonanemic patients. A hypochromic microcytic anemia is 
frequently found in iron deficient patients without chronic disease 
[ 9]. In our study MCV and MCH were also lower in anemic RA patients 
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without iron deficiency (considered as ACD patients) although they 
were higher than in iron deficient patients. Other studies also 
reported a lower MCV and MCH (2,7,10) in ACD patients. Anemia caused 
by iron deficiency is therefore not easily distinguished from ACD in 
patients with active RA by means of MCV and MCH. 
Reticulocytes were found to be higher in the anemic groups 
suggesting some response to the anemia. They tended to be higher in 
ACD but this was not significant. No difference in reticulocyte count 
was found between B12 and folic acid deficiency and the other types of 
anemia. 
In evaluating differences in cellular indices considering the 
dichotomy iron deficiency versus ACD it should be realised that these 
differences may be a little masked because of the coexistent presence 
of B12 or folic acid deficiency. B12 deficiency prevalence was the 
same in all three groups while folic acid deficiency was present more 
often in iron deficient patients. B12 deficiency had an important 
influence on cellular indices most pronounced in iron deficient 
patients. Patients with a combination of iron and B12 deficiency had a 
normochromic normocytic anemia. So if one relies on cellular indices 
many patients would have been classified as having ACD in which normal 
cellular indices are frequently found [6,7]. B12 deficiency usually is 
associated with a hyperchromic macrocytic anemia [11] although B12 
deficiency can occur in patients with normal cellular indices [12]. 
Iron deficiency is associated with a hypochromic microcytic anemia [9] 
so the combination results in normal indices. Folic acid deficiency 
exerted the same effects on cellular indices but these were not 
significant. 
Serum iron was below normal in all patients including the 
nonanemic patients although it was lower in both anemic groups. It is 
known that serum iron does not distinguish between iron deficiency and 
ACD [ 5, 7] which implies that it does not correlate with body iron 
stores. The low serum iron in nonanemics could be explained by the 
fact that in chronic disease, to some extent also present in this 
group, serum iron is low, possibly through trapping by ferritin [13] 
or the MPS [14,15]. 
The cause of the high prevalence of B12 deficiency among RA 
patients remains obscure. We found normal Schilling tests in most 
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patients and only one had gastric antibodies. Couchman [3] also 
reported normal Schilling tests in RA patients. Although significant 
effects upon MCV and MCH were shown, its relation with the anemia here 
is uncertain since B12 deficiency occurred in the same rate in 
nonanemics. Folic acid deficiency in contrast occurred predominantly 
among iron deficient RA patients suggesting malabsorption or dietary 
causes, which was not established in this study. The negative 
correlation of serum folic acid with RA disease activity might point 
to a role in ACD pathogenesis although it could also be argued that 
folic acid is utilized by proliferating synovial cells. For both B12 
and folic acid deficiency suppletion of the deficieny followed by Hb 
increase would prove some role in the anemia. Further studies are 
therefore necessary. In this thesis we only focused on effects of 
these deficiencies on diagnostic parameters while iron metabolism was 
further investigated in ACD (Chapter 4, 5, 6 and 8). 
It was shown that in most RA patients more causes of anemia were 
present simultaneously. We assume that iron deficient patients also 
have features of ACD since a negative correlation was found between Hb 
and disease activity (ESR) in the ACD group and parameters of disease 
activity were higher in iron deficient patients compared to 
nonanemics. This assumption was confirmed by the findings of a lower 
transferrin in iron deficient patients compared to nonanemics while 
ferritin was not low in both nonanemic and iron deficient patients 
while transferrin was found to be lowest and ferritin highest in ACD 
patients. Ferritin behaves like an acute phase reactant since it 
correlated with ESR and CRP. Among ACD patients iron deficiency can be 
detected most easily by means of a lower ferritin, although it is not 
subnormal [5]. The dichotomy ACD versus iron deficiency therefore is 
rather artificial. So, in fact we found that only 6 of 25 (24%) anemic 
patients had just one cause of anemia (ACD). 
All other patients had combinations of iron, B12 or folic acid 
deficiency, with or without ACD. In 2 patients (8%) both folic acid 
and B12 deficiency occurred. This implies not only that accurate 
diagnostic attention should be paid ~o the approach of anemic RA 
patients but also that several therapeutic possibilities in the 
treatment of anemia in RA are present apart from treating the RA. 
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In summary, we investigated the influence of iron, Bl2 and folic 
acid deficiency on diagnostic blood parameters of anemia in patients 
with ACD. All deficiencies were found to be highly prevalent in anemic 
RA patients. Only 24% of patients had just one type of anemia (ACD). 
Cellular indices were unreliable in the differential diagnosis since 
iron deficiency was marked by B12 and to a lesser extent by folic acid 
deficiency while MCV and MCH were lower in both iron deficiency and 
ACD. Ferritin is useful in the detection of iron deficiency among ACD 
patients. These findings suggest that studies on pathogenesis of 
anemia in RA should be interpreted with caution since usually more 
than one cause of anemia is present. Because deficiencies are present 
frequently several therapeutical pos~ibilities should be considered 
apart from treating the RA. 
CHAPTER 4 
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DIACWSTIC SIQUFICANCE OF ERY'IBROCYTE AND SEROLOGICAL PARAMETERS IN 
THE DETECTIW OF IRCN DEFICIENCY 1\I'I:NJ RA PATIENTS WI'IH ACD 
4. 1 INTRODUCTION 
As was shown in Chapter 3 the most frequent causes of anemia in RA 
are anemia of chronic disease (ACD) and iron deficiency. Others found 
frequencies of iron deficiency up to 70% in RA [1,2]. We found that, 
in case of coexistent B12 or folic acid deficiency, iron deficiency 
could be masked if one relies on cellular indices. It was also found 
that MCV and MCH were lower in both ACD and iron deficiency compared 
to nonanemic RA patients (Chapter 3). Therefore detection of iron 
deficiency among RA patients with ACD remains an important diagnostic 
problem. Stainable iron content in a bone marrow aspirate is a 
reliable parameter for detecting iron deficiency [3,4], but this is 
not a useful procedure considering the high prevalence of anemia in 
RA. Serum ferritin is a valid marker of iron deficiency in otherwise 
healthy patients [5], but it is less accurate in RA patients [1,2,6] 
because it behaves as an acute phase reactant [ 7]. Other parameters 
like transferrin and MCV correlate to some extent with stainable iron 
in bone marrow [2,8,9] while erythrocyte ferritin is reported to 
correlate with body iron stores as well [5,10]. 
We therefore performed a study to characterize the difference 
between ACD and ACD complicated by iron deficiency in RA, by means of 
simple erythrocyte and serological parameters, in order to predict the 
presence of iron deficiency by these parameters. 
4. 2 PATIENTS AND MElliODS 
4.2. 1 Demographic features 
Forty-four patients (9 male) with definite or classical 
rheumatoid arthritis and a serum hemoglobin (Hb) of less than 7.4 
mmol/1 and who did not receive iron treatment for at least six weeks 
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previously, entered the study after giving written informed consent. 
Other causes of anemia were excluded by history (present or past ulcer 
disease, other gastrointestinal disease or complaints, menorrhagia and 
hematuria), negative stools for occult blood, a normal vitamin B12, 
folic acid, coombs test, creatinin clearance and absence of 
microscopic hematuria. 
Patients were classified according to stainable bone marrow iron 
content. Group I (no stainable iron), group II (0-1; small amount), 
group III (1-2) and group IV (3 or more) (Chapter 2.9.1.). Groups I 
and II were considered iron deficient [3,4]. The other classification 
was based on cellular indices (range for MCV 80-96 fl and for MCH 
1600-2200 amol). Patients in group A were hypochromic microcytic, in B 
hypochromic normocytic, in c normochromic normocytic, in D 
normochromic microcytic and in E hyperchromic macrocytic. Mean age was 
63.4 years. A mean disease duration of 4.9 years was found, while 79% 
of patients were seropositive (Rose test) with a mean titer of 221 
(reciprocally). Sixty-nine percent of the patients received 
long-acting antirheumatic drugs and 78% used NSAIDs. These data, 
including age and sex did not differ significantly in the various 
subgroups. 
4.2.2. Laboratory procedures (for description see Chapter 2) 
Erythrocyte parameters: 
Hb, Ht, reticulocyte count, MCV, MCH. 
Iron status: 
Fe, transferrin, ferritin, ery-ferritin, iron absorption test and 
staining of a bone marrow aspirate for iron. 
Disease activity: 
ESR, CRP, C1qba. 
4.2.3 Statistics 
Sensitivity, specificity, validity and predictive value were 
calculated as described in 2.11.5. 
- 62 -
4. 3 RESULTS 
4.3.1 Relationship between stainable bone marrow iron content and 
erythrocyte parameters 
Iron deficiency (group I and II) was found in 24 patients (55%) 
(Table 1). Hb level did not differ in the four groups. 
MCV was smaller than 80 fl in 13 patients (54%) in groups I and 
II and in 2 patients (10%) in groups III and IV. MCV tended to be 
higher in group III but this was not significant. 
MCH was smaller than 1600 amol in 17 patients (71%) in groups I 
and II and in 7 (35%) in groups III and IV. MCH was higher in III 
compared to II (p<0.05). Reticulocytes were higher in IV compared to 
II (p<0.10). 
In Table 2 it is shown that hypochromic microcytic pattern was 
seen in 30% of the patients. Twelve of them (92%) were iron deficient. 
Hypochromic normocytic anemia occurred in 25%. Five of these ( 46%) 
were iron deficient. The most frequent type of anemia was normochromic 
and normocytic (39%). This was associated with an iron deficiency rate 
of 29% (5 patients). 
In the iron deficient groups 13 patients (54%) had a hypochromic 
microcytic anemia, 5 patients (21%) were classified as hypochromic 
normocytic and 1 (4%) as normochromic microcytic. 
In patients without iron deficiency (groups III and IV) 12 (60%) 
had a normochromic normocytic anemia, 6 (30%) were hypochromic 
normocytic, 1 ( 5%) hyperchromic macrocytic and 1 ( 5%) normochromic 
microcytic. 
Hb was significantly lower in hypochromic microcytic and 
hypochromic normocytic patients compared to normochromic normocytic 
patients (p<0.0025) (Table 2), while Hb was also lower in the 2 
patients with normochromic microcytic anemia (ns). 
4.3.2 Correlation between stainable bone marrow content and erythro-
cyte and serological parameters 
S-iron did not differ between groups I-IV (Table 1) and groups 
A, Band C (Table 2). S-iron was higher in D and E but this was not 
significant. 
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TABLE I Correlation of stainable bone marrow iron content (1=0, 
II=0-1, I/l=l-2, IV=>3) with erythocyte and serological 
parameters (values expressed as median and range). 
II III IV 
n=12 (27%) n=12 (27%) n=12 (27%) n=8 (19%) 
Erythrocyte parameters 
Hb (mmo1/1) 1 ) 6.0 (4.2-7.2) 6.1 (4.2-6. 7) 6.2 (5.2-7.1) 6.2 (5.4-7.0) 
MCV (f1) 80 (60-100) 80 (60-107) 86 (75-93) 83 (75-90) 
MCH (amo1) 1568 (1310-1730) 1516 (1140-2080) 1729 (1510-2060) 1603 (1410-1780) 
Reti"lt1ocytes 
( /00) 
Iron status 
21 (10-38) 
S-iron (,umo1/1) 5 (2-7) 
Iron absorption
2
) 4.5 (0.8-10.5) 
Transferrin 
(,umo1/1) 61 (33-81) 
S-ferritin 
(.ug/1) 17 (10-36) 
Ery-ferritin 
(.ug/1) 156 (96-1329) 
Disease activity 
ESR (mm/h) 75 (17-104) 
CRP (mg/1) 30 (3-93) 
24 (8-36) 
4 (1-8) 
1.6 (0.8-11.0) 
55 (33-85) 
30 (10-119) 
97 (51-233) 
74 (34-120) 
37 (2-117) 
C1qba (%) 18 (4-33) 20 (6-69) 
25 (13-41) 
5 (1-10) 
2.1 (0.9-3.5) 
50 (39-60) 
99 (21-247) 
128 ( 81-1863) 
85 (45-124) 
30 (5-122) 
24 (5-57) 
;: Hb in mmo1/1 x 1.61 = g/dl. 
Increase in serum iron expressed as a ratio (see Chapter 2.8). 
32 (19-45) 
5 (2-8) 
1.4 (0.8-2.2) 
48 (34-65) 
109 (45-246) 
132 ( 28-930) 
9l (40-116) 
56 (10-106) 
51 (18-100) 
TABLE 2 Relationship between cellular indices (normal values 
for MCV 80-96 fl and for MCff (1600-2200 amol), Hb and 
iron status (values expressed as median and range). 
hypochromic hypochromic normochromic normochromic hyperchromic 
Jllicrocytic normocytic normocytic microcytic macrocytic 
(A) (B) (C) (D) (E) 
n=l3 (30%) n=11 (25%) n=17 (39%) n=2 (4%) n=1 (2%) 
Hb (mmo1/1) 1 ) 5.9 (4.2-6.9) 6.1 (5. 7-6.6) 6.5 (5.4-7.1) 4.7 (4.2-5.2) 6.1 
s-iron (,umolj1) (1-7) 5 (2-7) 5 (1-10) 8 (2-14) 8 
Iron absorption 2 ) 2.3 (0.8-11.0) 1.6 (0.8-4.5) 1.8 (0.8-3.8) 5.6 (2.6-8.5) 3.3 
Transferrin (,umo1/1) 56 (33-81) 57 (40-70) 51 (34-70) 58 (48-67) 33 
s-ferritin (.ug/1) 20 (10-246) 80 (13-119) 95 (12-247) 49 (10-87) 21 
; ) Hb in mmo1/1 x l. 61 = g/dl. 
) Increase in serum iron expressed as a ratio (see Chapter 2. 8) . 
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Iron absorption was higher in group I compared to group II, III 
and IV (p<0.05) but data in group II versus group III and IV were not 
different (Table 1). It correlated negatively with ESR (r=-0.36, 
p<0.05) and CRP (r=-0.43, p<O.OS) in groups III and IV. 
Transferrin decreased from group I to IV (Table 1), but the 
difference was only significant between I and IV (p<0.05). It did not 
differ in respect to the type of anemia (Table 2), although a 
negative correlation was found between transferrin and the parameters 
MCV (r=-0.48, p<0.0005) and MCH (r=-0.40, p<0.0005). 
s-ferritin correlated with stainable bone marrow iron content 
(all differences between the groups I to IV were significant; p at 
least< 0.05); it was lowest in group I and highest in group IV (Table 
1). When cellular indices were normal s-ferritin was higher than in 
hypochromic microcytic patients (p<0.02) (Table 2). In group Bit was 
higher than in A (p<0.10). A negative correlation was found between 
s-ferritin and transferrin (r=-0.45, p<0.0005). 
The e-ferritin was highest in group I, but this was not 
significant. It did not correlate with any of the other parameters. 
ESR, CRP and C1qba tended to be higher in groups III and IV 
compared to I and II. In groups III and IV a negative correlation was 
found between Hb and ESR (r=0.40,p<0.05) but not with CRP and C1qba. 
Ferritin correlated with ESR (r=0.34,p<0.0025) and 
(r=0.38,p<0.01). 
4.3.3 Sensitivity, specificity, validity and predictive value of 
erythrocyte and serological parameters for the detection 
of iron deficiency (Table 3, Figure I) 
MCV (cut off point; c.o.p. 80 fl) has the highest specificity 
and predictive value for a single blood parameter. Its validity is low 
because of a low sensitivity. MCH (c.o.p. 1600 amol) has a little 
higher sensitivity but a lower specificity and predictive value. 
Combination of these parameters results in a higher, though still low 
validity, but this combination of parameters excluded 13 patients 
(30%) who had a combination of 1 parameter below and 1 parameter above 
its c.o.p. Transferrin (c.o.p. 50 pmoljl) has a low sensitivity and 
specificity and therefore a low validity. S-iron to transferrin ratio 
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does not increase the validity. The iron absorption test (not shown) 
had a low validity (51%). S-ferritin was the most valid single blood 
parameter (c.o.p. 50 pg/1). The combination of a MCV less than 80 fl 
and s-ferritin less than 50 pg/1 yields a 100% specificity and 
predictive value (16 patients (36%) had a different combination). If 
patients also had a transferrin more than 50 pmol/1 sensitivity became 
100% as well (27 patients (61%) had a different combination). 
TABLE 3 Sensitivity. specificity, validity and predictive value of 
erythrocyte and serological parameters and combinations for 
the detection of iron deficiency. 
Sensitivity Specificity Validity Predictive 
% % % value % 
MCV < 80 fl 52 90 71 87 
MCH < 1600 amol 71 65 68 71 
MCV < 80 fl 
MCH <1600 amol 72 92 77 93 
transferrin 
> 50 pmol/l 75 50 63 64 
iron/transferrin < 8% 65 65 64 68 
ferritin < 50 /ug/1 82 84 83 86 
ferritin < 50 pg/1 
MCV < 80 fl 79 100 89 100 
ferritin < 50 pg/1 
transferrin > 50 pmol/1 100 100 100 100 
MCV < 80 fl 
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FIGURE I Relation between stainable bone marrow iron (I=O, Il=0-1, 
cellular and serological 
is cut off point for the 
III=l-2, IV=3 or more) and 
parameters. Horizontal midline 
various parameters. Bars reflect 
relation to cut off points. 
the number of patients in 
..:V ( 80 FL. transferrin ) 50 JJ.-ll/1 ferritin (50 p.g/1 
II III IV II III IV II III IV II III IV 
12 
II III IV II III IV II III IV II III IV 
..:V ~80 FL. l«ll ~1600 aao1 transferrin~ 50 ,_,1/1 ferritin ~50 J4/l 
4. 4 DISCUSSION AND SUI-M4RY 
In this study we characterized the difference in erythrocyte and 
serological parameters between ACD with and ACD without iron 
deficiency and assessed the predictiveness of these parameters to 
detect iron deficiency. Stainable bone marrow iron content served as a 
standard for the diagnosis of iron deficiency [3,4]. 
Iron deficiency occurred in 55% of patients which is comparable to 
our finding of 52% (Chapter 3) and of other authors [1,2]. 
A reduced MCV was found in 34% of all patients but only in 10% of 
patients without iron deficiency. A low MCH was seen in 55% of 
patients and in 35% of patients without iron deficiency. Chernow [11] 
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found a reduced MCV in 32% and a reduced MCH in 49% of anemic RA 
patients with and without iron deficiency. 
Hypochromic microcytic anemia was associated most ( 92%) and 
normochromic normocytic anemia least (29%) with iron deficiency. These 
types of anemia were present in iron deficient patients in 54 and 21%, 
respectively. This implies that the pattern of cellular indices most 
frequently found in iron deficient patients without chronic disease 
[12] also is found in patients with active RA. Patients with a 
hypochromic microcytic or hypochromic normocytic anemia had a lower Hb 
suggesting that iron deficiency in these patients was more pronounced 
resulting in lower cellular indices. 
The majority of patients without iron deficiency, classified as 
having ACD, had either a normocytic normochromic (60%) or a normocytic 
hypochromic (30%) anemia. In ACD -in the absence of iron deficiency- a 
low MCH was frequently found (35%). The lower limit of MCH was changed 
from 1700 to 1600 amol in order to recognise concomitant iron 
deficie~cy because iron deficient patients also had a significantly 
lower MCH. MCV in ACD was generally higher though not significant and 
patients with iron deficiency generally may also have features of ACD 
since they have a certain disease activity. This would have masked a 
low MCV found in iron deficiency. Therefore lower limit of MCV was 
changed from 70 to 80 fl. If we had used normal ranges for MCV and MCH 
the anemias would have been classified a little different. It was 
shown before that, although MCV and MCH tended to be lower in both ACD 
and iron deficiency compared to nonanemic RA patients (Chapter 3), in 
iron deficiency these findings were much more pronounced. 
The need of these adaptions was supported by the finding of an 
optimal sensitivity, specificity, predictive value and validity using 
these lower limits for MCV and MCH as cut off points for the detection 
of iron deficiency. Sensitivity of both MCV and MCH as well as their 
combination was low while specificity of MCV and predictive value were 
highest for a single erythrocyte parameter. The combination of a low 
MCV and MCH resulted in a higher specificity and predictive value. 
Sensitivity was also higher but remained low. So, the finding of a 
hypochromic microcytic anemia suggests that in RA ACD is complicated 
by iron deficiency and only a few patients would have been classified 
as having ACD while being iron deficient if no bone marrow aspiration 
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is done. Hansen et al. [1] found a specificity of 100% for MCV but 
sensitivity was correspondingly low (24%) which would -if no bone 
marrow aspiration is done- result in underdetection of iron 
deficiency. Of the two patients with normochromic microcytic anemia 
one was iron deficient while the hyperchromic macrocytic pattern found 
in another patient with ACD could not be explained. 
No correlation existed between stainable bone marrow iron and 
serum iron, as we found earlier (Chapter 3), indicating that a low 
serum iron does not necessarily reflect low body iron stores. 
Serum transferrin was found to be higher in iron deficient 
patients while it was inversely correlated with MCV MCH and 
s-ferritin, which is in agreement with the general findings in iron 
deficiency [12]. For obtaining optimal validity, using transferrin, 
which in our study was low in the evaluation of iron deficiency, the 
upper limit should be changed from 74 to 50 prnol/1 because in ACD it 
is generally lower (Chapter 3). 
A s-iron to transferrin ratio (iron saturation) less than 15% 
generally is diagnostic for iron deficiency in patients without 
chronic disease [12]. we found that a cut off point (c.o.p) of 8% was 
most useful but it provided no more information than s-transferrin 
alone in the detection of iron deficiency. 
&-ferritin is a reliable parameter of iron deficiency in patients 
without chronic disease [5] but in chronic disease it behaves as an 
acute phase reactant [6,7], and therefore often a higher value is 
found, which may mask iron deficiency. In this study s-ferritin 
correlated with CRP and other parameters of disease activity like ESR 
and C1qba, confirming its acute phase behavior in active RA. Serum 
ferritin was highest in patients with a normochromic normocytic 
anemia. For the detection of concomitant iron deficiency lower limit 
of s-ferritin should be raised from 14 to 50 pgjl. At this level 
s-ferritin as a single parameter turned out to be the most valid and 
sensitive test in the evaluation of iron deficiency in patients with 
active RA. If s-ferritin values of 14-50 pgjl are found iron 
deficiency may be overlooked if one uses the usual lower limit of 14 
pgjl. Other authors used a c.o.p. of 60 pgjl [1,2] and 45 pg/1 [8]. 
The combination of s-ferritin and MCV resulted in a specificity 
and predictive value of 100% (c.o.p. 50 pg/1 and 80 fl, respectively) 
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which implies that iron deficiency is always present when finding this 
combination, but may be a little underdiagnosed (sensitivity 79%) if 
no bone marrow aspiration is perfonned. The addition of transferrin 
(c.o.p 50 pmoljl) to s-ferritin and MCV means proof for iron 
deficiency (validity of this combination was 100%). 
The combination of blood parameters is useful in the assessment of 
iron deficiency, but a number of patients cannot be evaluated in this 
way because they have other combinations (e.g., s-ferritin less than 
50 ,ug/1 and a MCV more than 80 fl; see Table 3). 
The erythrocyte-ferritin was of no value in the determination of 
iron deficiency in RA, confirming earlier results [10], though it is 
reported to be diagnostic in iron deficient patients without chronic 
disease [5]. 
The cause of the high prevalence of iron deficiency in RA found in 
our and other studies remains obscure. Since gastrointestinal blood 
loss, for instance due to the use of antirheumatic drugs, can occur 
subclinically and intermittently [13] this is not fully excluded in 
our patients. We found that iron absorption was highest among iron 
deficient patients. The negative correlation of iron absorption with 
RA activity found in ACD here, in which iron stores are present, might 
indicate that defective iron absorption is the result of active RA 
rather than a cause of ACD or iron deficiency. 
Patients with a hypochromic microcytic anemia had a higher iron 
absorption, although not significant. This is explained by the fact 
that these changes in cellular indices are associated with iron 
deficiency. The validity of the iron absorption test for detecting 
iron deficiency was low. 
Independent of its pathogenesis iron deficiency is considered to 
be protective in inflammation [14]. It is therefore questionable, 
after excluding all causes of iron deficiency, whether iron suppletion 
is indicated because it may exacerbate disease activity [15] though 
Hansen did not find deleterious effects of oral iron treatment in RA 
patients [ 1] . 
In summary, the present study showed a high prevalence of iron 
deficiency among anemic RA patients. ACD with and without iron 
deficiency was associated with a clearly different pattern of 
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erythrocyte and serological parameters. When iron deficiency is 
present in RA patients it generally coexists with ACD. Therefore the 
usual blood parameters should be adapted for ACD tend to direct MCV, 
transferrin and especially s-ferritin in an opposite way than iron 
deficiency does, while MCH is frequently lower than normal in ACD. The 
most specific and predicting parameter for the detection of iron 
deficiency was MCV, while s-ferritin is the most sensitive and valid 
test. Combination of MCV and s-ferritin raised specificity and 
predictive value to 100% and adding transferrin also raised 
sensitivity to 100%, though a number of patients are unevaluable using 
combinations. Iron absorption was shown to be higher in iron deficient 
patients. The iron absorption test and erythrocyte ferritin are of no 
value in determining iron deficiency in RA patients. Iron deficiency 
among RA patients with ACD can be detected accurately without bone 
marrow aspiration when normal ranges for blood parameters are adapted. 
CHAPl'ER 5 
-72-
PREDICTICI'l AND EVALUATICI'l OF THE EFFECT OF IRCX-I TRFA'IMENT 
IN ANEMIC RA PATIENTS 
5. I INTRODUCTION 
In the studies described in Chapter 3 and 4 it was shown that iron 
deficiency occurred in 52-55% in anemic RA patients. It was 
demonstrated that iron deficiency was mostly associated with 
hypochromic microcytic anemia whereas ACD was associated with either 
normochromic normocytic or hypochromic normocytic anemia (Chapter 4). 
OVerlap occurred, however, between iron deficiency and ACD in RA. We 
found that a MCV lower than 80 fl, a transferrin higher than 50 prnol/1 
and a serum ferritin lower than 50 pgjl predicted iron deficiency 
correctly. The ultimate proof of iron deficiency, however, rests upon 
a Hb rise following iron suppletion. Iron treatment of ACD in RA 
resulted in a transient Hb rise but in that study high parenteral 
doses were used [1,2]. Others saw no effect of iron treatment in RA 
patients with ACD [3]. 
Iron deficiency is considered to be protective in inflammatory 
diseases [4] and infection [5] while exacerbations of RA disease 
activity and synovitis are reported after iron treatment [1,2]. 
This study was performed to predict iron responsiveness of anemia 
in RA by means of simple erythrocyte and serological parameters and to 
evaluate whether iron treatment results in an increase of RA disease 
activity serologically. 
5. 2 MATERIALS AND METHODS 
5.2.1 Demographic features 
Twenty-eight patients (5 male) with definite or classical 
rheumatoid arthritis and a serum hemoglobin (Hb) of less than 7.4 
rnmol/1 who did not receive iron treatment for at least six weeks 
previously, entered the study after giving written informed consent. 
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Other causes of anemia were excluded by history (present or past ulcer 
disease, other gastrointestinal disease or complaints, menorrhagia and 
hematuria), negative stools for occult blood, a negative Coombs test, 
a normal vitamin B12, folic acid, creatinin clearance and absence of 
microscopic hematuria. 
Patients were classified according to stainable bone marrow iron 
content. Group I (no stainable iron), group II (0-1; normal to very 
small amount, group III [1-2] and group IV (3 or more). Groups I and 
II were considered iron deficient (6,7). The other classification was 
based on cellular indices (range for MCV 80-90 fl and for MCH 
1600-2200 amol). Patients in group A were hypochromic microcytic, in B 
hypochromic normocytic, in C normochromic normocytic, in D 
normochromic microcytic and in E hyperchromic macrocytic. Mean age was 
64 (48-79) years. A median disease duration of 4.2 (1-18) years was 
found, while 71% were seropositive (Rose test) with a mean titer of 
261 (reciprocally). 61% Percent of the patients received long-acting 
antirheumatic drugs and 72% used NSAID's. These data, including age 
and sex did not differ significantly in the various subgroups. 
5.2.2 Laboratory procedures 
The following parameters, described in Chapter 2, were assessed: 
Erythrocyte parameters: 
Hb, MCV, MCH, reticulocyte 
Iron status: 
count, 
Serum iron, transferrin, ferritin, 
Disease activity: 
ESR, CRP and C1qba. 
Iron absorption test. 
Bone marrow aspirate (after sternal puncture) was stained for iron. 
5.2.3 Treatment schedule 
Patients were treated for 6 weeks with an daily dose of (oral) 
Fero-Gradumet (Abbott BV, Amstelveen, The Netherlands), containing 105 
mg elementary iron. After 2 weeks reticulocyte count was repeated and 
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after 6 weeks all laboratory procedures were repeated except 
reticulocyte count, iron absorption and bone marrow aspiration. 
5.2.4 Statistics 
Sensitivity, specificity, validity and predictive value were 
calculated as described in 2.11.5. 
5. 3 RESULTS 
5.3.1 Baseline characteristics in relation to bone marrow iron content 
Sixteen patients (57%) were iron deficient (groups I and II). 
Table 1 and 2 show baseline characteristics and classification of the 
anemia in relation to cellular indices. Data and classifications at 
baseline were approximately the same as described in Chapter 4 (4.3.1 
and 4.3.2). 
5.3.2 Responsiveness of the anemia to iron treatment 
A Hb increase after 6 weeks of treatment with ferrosulphate was 
found in 17 patients (61%). Median Hb increase was 0.6 mmol/1 (range 
0.1-1.8). In all 44 patients a median Hb increase of 0.3 mmol/1 (range 
-1.2-1.8) was seen. 
a) Relationship between bone marrow iron content and response to 
treatment 
As is shown in Table 1 and 3 only in iron deficient patients (group 
I and II) a Hb rise occurred. The rise among responders was highest in 
group I but the response rate was lower than in group II. 
After treatment 11 of the iron deficient patients (69%) were still 
anemic. 
A slight Hb decrease was found among patients with ACD (III and 
IV). All these patients remained anemic after treatment. 
TABLE 1 Relationship between bone marrow iron content (I=O, II=0-1, III=l-2, IV~3), baseline (B) and data after (A) 6 weeks of 
iron treatment (values expressed as median and range). Age and sex did not differ in groups I-IV. 
I II III IV 
n=8 (28.6%) n=8 (28.6%) n=9 (32.1%) n=3 (10.7%) 
B A B A B A B A 
a) Erythrocyte parameters 
Hb (mmo1/1) 1 ) 
. 
6.9+ 5.9 6.6 6.2 6.3 6.2 6 0 7 6.2 
(4.2-6.5) (6.0-7.9) (5.4-6. 7) (6.0-7.8) (5.4-7.1) (5.5-7.3) (6.5-7.0) (5.8-6.4) 
. 
MC\1 (fl) 80 85 81 87 86 82 84 83 
(60-100) (72-107) (72-107) (72-105) (81-98) (72-96) (80-90) (81-85) 
MC!I (amo1) 1583 1566 1549 1623 1683 1665 1643 1547 
(1310-1730) (1370-1910) (1340-2080) (1280-2040) ( 1510-1950) ( 1520-1910) ( 1560-1780) ( 1520-1570) 
. • Reti0u1o"¥yes 21 31 24 32 25 36 26 36 
( /00) (10-44) (25-46) (8-49) (15-71) (13-31) (4-49) (19-31) (32-48) 
b) Iron status 
• .. 6+ o..n Iron (J1111o1/1) 5 10 4 9 5 5 5 
r- (2-7) (3-21) (1-8) (3-16) (3-10) (3-20) (5-8) (3-8) 
Iron absorption 8.1 1.7 2.0 1.2 
(0.8-10.5) (1.0-11.0) (0.8-3.5) (0.8-1.4) 
Transferrin 63 59 52 59 52 54 57 51 
(JIIl101/1) ( 40-81) (36-75) (33-62) (33-73) (45-60) (44-63) (52-65) (44-62) 
. 
Ferritin (pg/1) 18 16 26 31 109 65 77 191 
(10-58) (10-63) (10-119) (10-55) (21-247) (17-153) (45-126) (18-363) 
c) Disease activity 
ESR (mm/h) 75 48 82 54 84 70 49 68 
(17-96) (15-140) (53-120) (24-100) (45-124) (7-120) (40-47) (26-108) 
CRP (mg/1) 21 27 34 10 30 43 23 37 
(3-93) (4-67) (2-78) (4-25) (6-102) (2-67) (18-76) (5-38) 
Clqba (%) 14 13 27 34 25 29 26 15 
(4-33) (3-36) (8-69) (13-55) (7-57) (5-63) (19-80) (-) 
; ) Hb in mmol/1 x 1. 61 = g/dl. 
) Reticulocyte count was assessed before and after 2 weeks of ir~n treatment. 
Significance level before vs after treatment: *p<O.lO; **p<O.OS; p<O.Ol. 
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TABLE 2 Relationship between cellular indices (range for MCV 
80-96 fl and for MCH 1600-2200 amol) and response to 
treatment. Values expressed as median with range. 
Hypochromic 
lib 
(mmol/1) 
Microcytic 6.1 
n=8 (29%) (5.4 - 6. 7) 
(A) 
Hypochromic 
Normocytic 6.2 
n=8 (29%) (5.4 - 6. 7) 
(B) 
Normochromic 
Normocytic 6. 6 
n=10 (36%) (5.8 - 7.1) 
(C) 
Normochromic 
Microcytic 
n=1 (3%) 4.2 
(D) 
Hyperchromic 
Macrocytic 
n=1 (3%) 6.1 
(E) 
Number of 
responders (%) 
7 (88) 
4 (50) 
4 (40) 
1 (100) 
1 (100) 
Hb rise1 ) in 
responders (%) 
0. 7 (12) 
(0.3- 1.1) 
0.3 (5) 
(0.1 - 1.0) 
0.2 (3) 
(0.1- 1.2) 
1.8 (43) 
0.2 (3) 
Hb rise1 ) in 
all patients(%) 
0.6 (10) 
(0.0 - 1.1) 
0.0 (0) 
(-0.2 - 1.0) 
-0.1 (2) 
(-1.2 - 1.2) 
1.8 (43) 
0.2 (3) 
p<O .01 
ns 
ns 
ns 
ns 
; ~ Hb rise is written as absolute value and percentage of initial value in parenthesis. 
P value was calculated from Hb change in all patients within a subgroup. 
TABLE 3 Relationship between bone marrow iron content and response to 
treatment (!=0, II=0-1, III=l-2, IV=3). Values expressed as 
median with range. 
I 
n=8 
II 
n=8 
III 
n=9 
IV 
n=3 
Responders 
5 (63) 
8 (100) 
4 (44) 
0 
Hb rise1 > in 
responders 
0.9 (15%) 
0.3-1.8 
0.6 (10%) 
(0.1-1.1) 
0.2 (2%) 
(0.1-0.2) 
0 
Hb rise1 > in 
all patients 
0.5 (9%) 
(-0.3-1.8) 
0.6 (10%) 
(0.1-1.1) 
-0.1 (2%) 
(-0.9-0.2) 
-0.5 (8%) 
(-0.2-1.2) 
Significance2 > 
level 
0.10 
0.01 
ns 
ns 
1
> Hb rise in mmol/1 written as absolute value and percentage of 
initial value in parenthesis. 
2
> P value was calculated from Hb change in all patients within a 
subgroup. 
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b) Relationship between cellular indices and response to treatment 
Table 2 shows that a significant Hb rise is only found in patients 
with a hypochromic microcytic anemia, the response rate being 88%. Hb 
remained unchanged or decreased slightly in groups B and C. In D and E 
both patients responded. 
5.3.3 Prediction of responsiveness of the anemia to iron treatment 
MCV showed to have the highest specificity and predictive value 
for the prediction of a Hb rise (Table 4). At a cut off point of 80 fl 
sensitivity was low, however, it correlated strongly with a Hb rise. 
MCH had a little higher sensitivity but validity did not differ 
from MCV. 
Combination of MCV and MCH resulted in a higher validity 
compared to MCV and MCH separately (71 vs 61%). 
The iron absorption test was not predictive for a Hb rise (not 
shown). 
Transferrin was a sensitive but not specific test in the 
prediction of a Hb rise. 
Combination of transferrin and MCV resulted in a higher validity 
(83 vs 61%). 
Ferritin was the most valid single blood parameter. It was found 
to correlate negatively with a Hb rise. 
Combination of ferritin and MCV resulted in a 100% specificity 
and predictive value but sensitivity was lower than ferritin alone. 
5.3.4 Effect of iron treatment on erythrocyte and 
parameters 
a) Change in erythrocyte parameters 
serological 
MCV rise was associated with Hb rise (r=0.71; p<0.0025) and s-iron 
(r=0.61; p<0.0025). Hb change did not.correlate with changes in other 
parameters. Table 1 shows that MCV tended to increase in group I and 
II after treatment. 
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TABLE 4 Sensitivity, specificity, validity and predicitive 
value of erythrocyte and serological parameters for 
the prediction of a Hb rise. 
Sensitivity Specificity Validity Predictive Coefficient1 ~f 
(%) (%) (%) value (%) correlation 
MCV < 80 f1 41 90 61 88 r~0.52;p<0.005 
MCH < 1600 amo1 65 55 61 69 r=-0.25;ns 
MCV < 80 fL 64 83 71 88 
MCH < 1600 amol 
Transferrin 82 33 61 70 r=0.24;ns 
> 50 pmo1/1 
Transferrin 88 75 83 88 
> 50 pmo1/l 
MCV < 80 fL 
Ferri tin < 50 pg/1 73 82 78 85 r~0.49;p<0.01 
Ferri tin < 50 pg/1 64 100 88 100 
MCV < 80 fL 
1) Correlation of initial value of parameter with Hb rise. 
TABLE 5 Change in cellular 
Hb response rate. 
vertical axis. 
horizontal axis. 
1600-2200 amol). 
indices after iron treatment in relation to 
Initial classification is shown on the left 
Classification after treatment on the 
(Normal range for ACV 80-96 f I and for ACH 
Hypochromic lib rise Hypochromic Hb rise Normochromic Hb rise Normochromic lib 
microcytic normocytic normocytic microcytic 
rise 
number(%) number(%) number(%) number(%) number(%) number(%) number(%) number(%) 
Initial 
classi-
fication 
Hypochromic 5 5 1 1 
!~ncytic (83) (100) (17) (100) 
(A) 
Hypochromic 1 1 3 3 2 
::~cytic (14) (100) (43) (43) (67) 
(B) 
Normochromic 0 4 4 3 2 1 
Normocytic (40) (40) (75) (20) (50) 
n=10 
(C) 
1) In 2 patients indices were not reassesed. 2) In 1 patient indices were not reassessed. 
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MCH increased in II but decreased significantly in I and II after 
treatment. 
In group A cellular indices remained unchanged in the majority 
(Table 5). All patients, including the one who became normocytic, had 
a Hb rise. 
In group B a slight Hb rise was only found in 2 of 3 patients whose 
MCH turned to normal and in 1 in which MCV decreased. 
In group C a small Hb increase was observed in 3 of 4 patients when 
indices did not change and in 1 of the 2 in which MCV decreased. 
In group D and E indices were unchanged after treatment with a Hb 
rise in both patients. 
The reticulocyte count 2 weeks after initation of treatment tended 
to rise in all groups (Table 1). 
b) Change in parameters of iron status 
S-iron rose in group I, II and III. No correlation was found 
between s-iron rise and iron absorption. Transferrin did not change 
significantly after treatment. Ferritin decreased in group III and II 
while an unsignificant increase was seen in I and IV (Table 1). 
Ferritin change was inversely correlated with transferrin change 
(r=0.56; p<0.0025) but not with Hb change. 
c) Change in parameters of disease activity 
ESR decrease in group I and II separately was not significant 
(Table 1). If they were taken together (iron deficient patients) the 
decrease was significant (p<O.OS). In III and IV no significant change 
was seen. 
CRP and C1qba did not change significantly in the various 
subgroups. 
Ferritin change correlated with ESR change in groups III and IV 
together (r=0.83; p<O.OS). It correlated with CRP change in I and II 
together (r=0.88; p<O.OOOS) and in III and IV together (r=0.70; 
p<0.025). In the case of C1qba a correlation was only seen in groups I 
and II (r=0.60; p<0.025). 
Hb change correlated with a change in ESR in all patients (r=0.34; 
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p<0.05) but not in groups I and II alone. No correlation existed 
between CRP and C1qba change with Hb change. 
In Table 6 it is shown that in iron deficient patients no 
differences in Hb increase were seen between patients in which 
parameters of disease activity either remained unchanged (decrease 
less than 10%) or increased on one hand and patients with a decrease 
in these parameters on the other. The same was found for a Hb decrease 
in groups III and IV. 
TABLE 6 Relationship between Hb change and change in ESR, CRP and 
Clqba (Hb values expressed as median with range). 
ESR =/1' 
ESR -1-
CRP =/1' 
CRP -1-
C1qba =/1' 
C1qba -1-
I and II 
Hb change ( nunoljl) 
(number) 
0.6 (0.1-1.8) 
(n=8) 
0.5 (0.2-0.9) 
(n=8) 
0.8 (0.3-1.8) 
(n=9) 
0.5 (-0.1-1.0) 
(n========7) 
0. 7 ( 0.2-1.4) 
(n=ll) 
0.6 (0.2-1.8) 
(n=5) 
=/1' means less than 10% decrease or increase 
-1- means more than 10% decrease 
III and IV 
Hb change (nunol/1) 
(number) 
0.5 (-1.2-0.1) 
(n=5) 
0 • 0 ( -0 . 6-0 . 2 ) 
(n=7) 
-0.2 (-1.2-0.2) 
(n=8) 
-0.3 (-0.9-0.2) 
(n=4) 
-0.2 (-0.4-0.2) 
(n=10) 
-0.2 (-1.2-0.2) 
(n=2) 
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5. 4 D/ SCUSSION AND SUIM4RY 
This study was performed to predict iron responsiveness of anemia 
in RA by means of simple erythrocyte and serological parameters and to 
evaluate whether iron treatment results in increase of serological 
parameters of disease activity. 
We found that 57% of patients were iron deficient which is in 
agreement with a prevalence earlier described (Chapter 3: 52% and 
Chapter 4: 55%). 
Most iron deficient patients had a hypochromic microcytic or 
hypochromic normocytic anemia and those with ACD presumably had a 
normochromic normocytic or a hypochromic normocytic anemia as well as 
values from serum iron status and parameters of disease activity. 
These patterns did not differ from those described in the study in 
Chapter 4, which is to be expected since most patients studied here 
were derived from a subset of patients described in Chapter 3 and 4. 
5.4.1 Responsiveness of the anemia to iron treatment 
Only iron deficient patients had a significant Hb rise after 6 
weeks of iron treatment. The response rate was 81% and in these 
patients median Hb increase was 0.8 mmoljl. The response rate was 
highest among patients with a hypochromic microcytic anemia ( 88%; Hb 
rise 0.7 mmol); 2 other iron deficient patients with different 
cellular indices also responded. Reassessment showed no other 
deficiencies, however, in these patients. Others found a response rate 
of 80% in iron deficient RA patients who were tr~ated for 3 months 
[3]; the response rate therefore seems not to increase after prolonged 
iron therapy. Hb increase was higher in this study, however (1.5 
compared to 0.8 mmol/1 in our study). After treatment 69% of iron 
deficient patients still were anemic in our study. Continuation of 
treatment after 6 weeks possibly might have resulted in a further Hb 
increase. It must be realized, however, that most of all anemic and 
iron deficient patients probably also have features of ACD which may 
limit a maximal Hb increase. On the other hand, 83% of patients 
initially classified as having a hypochromic microcytic anemia had the 
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same indices after treatment, suggesting that they were still iron 
deficient. MCV and MCH did not change significantly after treatment. A 
problem in the evaluation of iron treatment is that the longer the 
patients are treated with iron the higher the chance that disease 
activity will decrease when patients have antirheumatic treatment 
simultaneously. So, if disease activity is decreased- which is 
associated with a Hb rise [8] - it is difficult to establish the role 
of iron treatment. 
In patients without iron deficiency and most patients with 
normal cellular indices there was no significant Hb rise and all 
remained anemic. Most of patients with normal indices at baseline did 
not change their indices or became hypochromic. In groups III and IV a 
slight overall Hb decrease was found. In some patients Hb decreased 
more than 10%. In these patients ESR increased and MCH decreased. 
Since severity of ACD and hypochromasia are correlated with disease 
activity to some extent [8,9,10] this could explain the Hb decrease in 
these patients. A temporary rise in Hb in RA patients with ACD 
following iron treatment was found by others [1,2] but they used high 
parenteral doses of iron. 
5.4.2 Change in parameters of disease activity and iron status 
Parameters of disease ac~ivity tended to decrease in most 
patients after 6 weeks but this was only significant in groups I and 
II. In group III and IV a Hb decrease and ESR increase were strongly 
correlated, explaining most of the negative correlation between Hb and 
ESR change since this correlation was not found in iron deficient 
patients. CRP and C1qba changes were not correlated with a Hb change. 
Furthermore, it was shown that Hb changes were the same in patients 
with a decrease or increase in parameters of disease activity (Table 
6). So, although a decrease in disease activity is associated with a 
Hb rise [8] it played a minor role in this study. 
S-iron rose in all groups except IV but obviously this increase 
resulted in a higher bone marrow availability only in iron deficient 
patients, since no Hb rise was found in III and IV. Ferritin change, 
although not consistent, correlated with changes of ESR and CRP in ACD 
patients confirming its acute phase behavior [11]. Transferrin did not 
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decrease in iron deficient patients probably because these patients 
already had features of ACD masking a further decrease after iron 
treatment (Chapter 3,4). 
In contrast to what others reported [2] we could not demonstrate 
any harmful effect of 6 weeks of iron treatment on serological 
parameters or disease activity in RA patients with or without iron 
deficiency. 
The reticulocyte count after 2 weeks was higher in all groups 
suggesting an increased erythropoiesis. It was not correlated with a 
Hb rise after 6 weeks, however. Possibly during the initial phase of 
iron treatment a temporary increased bone marrow iron availability is 
present, even in ACD patients, while it is trapped by the mononuclear 
phagocyte system [12,13,14] in a later phase in patients with ACD. 
5.4.3 Prediction of response to iron treatment 
MCV turned out to be the most specific (90%) and predictive 
(88%) parameter of a Hb response. Using grade 0-1 stainable bone 
marrow iron as a standard Hansen [3] found a predictive value of 83%. 
Sensitivity was low. MCH alone was not useful while the combination of 
MCV and MCH resulted in a raised sensitivity (64%) and validity (71%) 
but both are still low in the prediction of a response to treatment. 
Sensitivity of transferrin (82%) was reasonable but predictive value 
(70%) and specificity (33%) were low. The combination of a specific 
test (MCV) with a sensitive test (transferrin) resulted in a 
reasonable validity (83%). s-ferritin was the most valid single test 
(78%). Its predictive value was 85% which is comparable to what Hansen 
[3] found (83%). The combination of MCV and s-ferritin proved to be 
useful. Both specificity and predictive value were 100%. This means 
that if MCV is less than 80 fl and s-ferritin less than 50 pg/1 the 
patient will definitely respond to iron treatment. On the other hand 
if both values are above the cut off points some patients will also 
respond (sensitivity of 64%). It should be realized, however, that a 
combination of parameters restricts the number of patients to be 
evaluated with these parameters because different combinations occur. 
(eg. 1 parameter above and 1 parameter under the cut off point). 
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In summary, in this study it confirmed that many anemic RA 
patients have concomitant iron deficiency (diagnosed by means of 
staining a bone marrow aspirate for iron). Only patients with iron 
deficiency and cellular indices associated with iron deficiency show a 
significant Hb rise after 6 weeks of treatment with iron. 
In the prediction of a Hb rise following oral iron 
administration MCV is the most specific and predictive single 
bloodparameter. Iron absorption was higher in iron deficient patients 
compared to patients without iron deficiency, but this test did not 
predict a Hb rise. Transferrin is the most sensitive test while 
ferritin is the most valid test. Combination of MCV and ferritin 
predicts a response in all patients although some patients with values 
above the cut off point of these parameters also respond. Bone marrow 
aspiration therefore rarely is indicated. 
After 6 weeks the majority of patients are still anemic which 
suggest that either treatment was too short or the presence of ACD 
limited a further increase. Some parameters of disease activity tended 
to decrease after 6 weeks but after statistical analysis this turned 
out to be a minor contribution to the Hb rise. This also implies, 
however, that iron treatment did not result in increased serological 
RA activity. 
OIAPTER 6 
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IMPAIRED IIOl UPI2\KE AND TRANSFERRIN BINDING BY ERY'l'HROBIASTS IN 
ANEMIA IN RHEUMATOID ARTHRITIS 
6. I INTRODUCTION 
As was shown in Chapter 1 many factors are associated with ACD. 
Iron metabolism has been extensively studied in RA patients with ACD. 
It was first thought that decreased iron absorption might underly the 
development of ACD [1]. We found that iron absorption in nonanemics 
did not differ from those with ACD [2], whereas in iron deficient RA 
patients it was increased (Chapter 4, 5). In patients with ACD iron 
stores are increased by definition so the impaired iron absorption 
found in ACD is rather the result of RA disease activity than a cause 
of ACD or iron deficiency in RA. 
Iron treatment in RA patients with ACD does not result in 
increased erythropoiesis (Chapter 5). Apparently, since in ACD bone 
marrow MPS-iron is increased, iron incorporation into erythroblasts 
in ACD is blocked. Some authors speculated that the MPS retains iron 
in ACD [3] although this turned out to be unspecific for ACD [4]. The 
same held through for ineffective iron turnover which was first found 
in RA and ACD [5] but later in iron deficient RA patients [6]. In 
another study 59 Fe-haem release from cultured erythroblasts was shown 
to be increased suggesting ineffective erythropoiesis [7]. 
It is not known, however, whether iron incorporation and 
transferrin binding by erythroblasts is impaired in ACD which as such 
might explain a decreased erythropoiesis in RA and ACD. The method for 
measuring these parameters were described by Katz et al. [8] and Van 
der Heul et al. (9] and was shown to be reliable. 
We therefore examined iron incorporation and transferrin binding 
by erythroblasts in healthy controls and RA patients with and without 
anemia in order to determine a potential pathogenetic role of these 
factors in RA and ACD. 
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6. 2 PATIENTS AND METHODS 
6.2.1 Patients 
Bone marrow from 5 healthy bone marrow donors and 18 patients with 
definite or classical RA were studied after receipt of the patient's 
written informed consent. 
Group I (n=5) consisted of bone marrow transplantation donors 
(healthy controls), group II (n=5) consisted of nonanemic RA patients, 
group III (n=6) of RA patients with ACD and group rv (n=7) of iron 
deficient RA patients. Mean age was 58 years, mean disease duration 
had been 7 years (3-16), 13 (72%) of them used long-acting 
antirheumatic drugs and 15 (83%) used nonsteroidal anti-inflammatory 
drugs. These characteristics did not differ significantly among the 3 
RA groups. We excluded patients who had treatment with iron, vitamin 
Bl2 or folic acid and those with B12 or folic acid deficiency, a 
present or past ulcer history, hematuria, menorrhagia, possible occult 
fecal blood test, hemolysis (Coombs, haptoglobin) and a decreased 
creatinin clearance. 
6.2.2 Laboratory procedures 
The following parameters described in Chapter 2 were assessed: 
Erythrocyte parameters: 
Hb, Ht, reticulocytes, MCV and MCH. 
Iron status: 
serum iron, transferrin, iron saturation, ferritin. 
RA disease activity: 
ESR,CRP. 
Bone marrow aspirate (posterior iliac crest puncture) 
- assessment of stainable bone marrow iron 
- preparation of cell suspension (20 ml bone marrow) for separation of 
mononuclear cells (2.9.2). 
- asessment of iron incorporation and transferrin binding to 
erythroblasts (Chapter 2.10). 
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Table I Parameters of erythropoiesis in group I-IV. Data are 
expressed as median with range. 
Controls 
I 
(n=5) 
Hb 8.1 
(mmol/1) (7.7-8.2) 
MCV 93 
(fl) (86-95) 
MCH 1940 
(amol) (1770-1950) 
Retics 16 
( 
0 
/00 ) ( 3-21) 
* Erythroblasts 3 
(
0 ;o) (2-18) 
* 
Nonan/RA 
II 
(n=5) 
7.7 
(7.4-8.7) 
93 
(86-116) 
1890 
(1820-2370) 
10 
(1-13) 
8 
(1-26) 
ACD/RA 
III 
(n=6) 
6.7 
(6.6-6.9) 
90 
(81-98) 
1900 
(1540-2040) 
24 
(5-30) 
12 
(4-29) 
Fe-def/RA 
IV 
(n=7) 
6.5 
(4.3-7.1) 
85 
(61-95) 
1690 
(1090-1920) 
15 
(5-26) 
5 
(1-27) 
Percentage of erythroblasts reflects nucleated erythroid cells in a 
cell culture smear without Epo stimulation before iron and 
transferrin addition. 
Table 2 Parameters or iron status and disease activity in groups 
I-IV. Data are expressed as median with range. 
Iron 
(.umoljl) 
Transferrin 
(.umol/1) 
Iron sat 
(0 /0) 
Ferritin 
(.ug/1) 
ESR 
(nurvh) 
CRP 
(mg/1) 
Controls 
I 
(n=5) 
9 
(5-12) 
50 
(48-52) 
18 
(10-25) 
18 
(12-28) 
26 
(16-46) 
4 
(2-6) 
Nonan/RA 
II 
(n=5) 
8 
(1-9) 
56 
(46-76) 
12 
(2-23) 
33 
(10-326) 
36 
(21-65) 
22 
(2-41) 
ACD/RA 
III 
(n=6) 
9 
(4-11) 
50 
(41-58) 
16 
(8-27) 
117 
(38-432) 
60 
(52-101) 
28 
(10-121) 
Fe-def/RA 
IV 
(n=7) 
4 
(2-10) 
56 
(52-81) 
6 
(4-15) 
16 
(10-53) 
57 
(32-104) 
20 
(2-78) 
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6. 3 RESULTS 
6.3.1 Parameters of erythropoiesis (Table 1) 
MCV and MCH were significantly lower in group IV compared to I and 
II (pat least 0.05). 
Reticulocyte count and percentage of nucleated erythroblast did 
not differ significantly between the four groups. 
6.3.2 Parameters of iron status and disease activity (Table 2) 
Serum iron and iron saturation was slightly lower in group IV 
compared to I and III (p<O.lO). 
Ferritin tended to be higher in group II compared to I (p<O.lO). 
It was higher in III compared to I, II and IV (pat least 0.01), while 
in IV it was lower than in II and III (pat least 0.05). 
ESR was higher in group III compared to I and II (p<0.01); in IV 
it was also higher than in I and II (pat least 0.05). It correlated 
negatively with Hb in II and III (r=0.78; p<0.05). 
CRP was higher in group III compared to I (p<0.01), II and III 
(p<0.05). It correlated negatively with Hb in II and III (r=-0.67; 
p<0.05). 
6.3.3 Iron incorporation into and transferrin binding to erythroblasts 
(Table 3A and 3B; Figure !A and !B) 
Iron incorporation was lower in group III compared to I and II at 
all times (pat least 0.05). It tended to be lower in III compared to 
IV at 30, 60 and 120 minutes (p<O.lO). In IV it was only lower 
compared to I at 30 and 60 minutes (p<0.05) whereas it did not differ 
from II. The difference between I and II was not significant. A 
negative correlation was found between iron incorporation and CRP in 
group III (r=-0.93; p<O.Ol). Iron incorporation correlated positively 
with serum transferrin in groups II and III (r=0.40; p<0.02). 
Transferrin binding was lower in group III compared to I at all 
times (pat least 0.05). The differences between III and II and IV 
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were not significant. In I it was higher compared to II at 2 minutes 
(p<0.05) whereas at 30, 60 and 120 minutes it tended to be higher 
(p<O.lO). Transferrin binding correlated positively with serum 
transferrin in groups II and III (r=0.55; p<0.05). 
Table 3 Iron incorporation into (A) and transferrin binding to (B) 
erythroblasts in groups I-IV. Data are expressed as median 
range. 
Controls NonanjRA ACD/RA Fe-defjRA 
I II III IV 
(n=5) (n=5) (n=6) (n=7) 
A: Iron incorporation* 
(pmol;2xl0 cells) 
1 25 14 6 16 
(3-52) (10-30) (4-40) (3-48) 
2 55 27 11 20 
(6-79 (18-85) (5-47) (4-102) 
3 61 44 11 35 
(11-119) (15-114) (5-73) (5-158) 
4 92 65 25 41 
(15-174) (20-381) (9-113) (10-264) 
B: Transferrin bindin~ 
(pmol;2x106 cells) 
1 26 9 6 11 
(11-35) (3-44) (3-12) (3-55) 
2 21 6 5 10 
(7-40) (3-44) (2-14) (2-42) 
3 15 5 4 9 
(7-25) (3-28) (2-10) (2-38) 
4 15 5 4 9 
(8-25) (2-28) (2-10) (2-42) 
* Iron incorporation and transferrin binding per 2xl06 erythroblasts. 
(1=2 min, 2=30 min, 3=60 min, 4=120 min after addition of 59 Fe-125 I 
transferrin) • 
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FIGURE I Iron incorporation into nucleated erythroblasts (A) and trans-
ferrin binding by transferrin (B) (I= 2 min, 2= 3059min 1253= 
60 min and 4= 120 min after a~dition of Fe- I 
transferrin). Median values are encircled and 
connected by broken lines. 
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6. 4 DISCUSSION AND SUW\44RY 
Iron metabolism has been extensively studied in ACD and RA. 
Decreased iron absorption, once thought to be cause of ACD or iron 
deficiency [1], was later shown to be a secondary phenomenon of active 
RA [2,10]. Decreased iron availability, due to an impaired iron 
release by the MPS is another postulated theory [3] but in later 
studies it was found not to be related to ACD [4]. Various methods 
have been used to show that ineffective erythropoiesis, i.e. 
ineffective iron turnover by bone marrow, is a pathogenetical factor 
in ACD [5]. However·, in other studies it was also associated with iron 
deficiency [6]. Williams et al. [7] found that 59 Fe-haem release, as a 
parameter of ineffective erythropoiesis, was increased in patients 
with RA and ACD and not in nonanemic or iron deficient RA patients. 
Their results, however, do not discriminate between impaired Hb 
synthesis or reduced erythroid precursor survival. 
About iron uptake and transferrin binding by erythroblasts in RA 
and ACD no data exist. We therefore examined a potential 
pathogenetical role of decreased iron uptake and transferrin binding 
by erythroblasts in patients with RA and ACD. The method for 
measurement of these parameters, using 59 Fe bound to 125 I-transferrin, 
was shown to be reliable in previous studies [8,9,11,12]. 
We found iron incorporation by erythroblasts to be significantly 
reduced in patients with RA and ACD compared to healthy controls and 
nonanemic RA patients. It was shown that it correlated negatively with 
CRP, a RA disease parameter, in ACD patients which implies that the 
decrease in iron incorporation might be directed by RA disease 
activity. These findings suggest that decreased iron 
into erythroblasts might be a pathogenetical factor 
incorporation 
in ACD. Iron 
incorporation in ACD was also lower than in iron deficient RA patients 
but less clear. The difference might have been masked by the fact that 
disease activity was approximately similar in these two groups. From 
these data, however, it cannot be differentiated whether iron 
transport through the erythroblast membrane is impaired or whether 
iron is retained by monocytes or macrophages which are present in the 
medium. It is postulated that iron incorporation into erythroblasts 
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takes place through transferrin-receptor mediated endocytosis [13,14]. 
The iron is released from transferrin at the receptor site after which 
it is transported to the mitochondria [15]. Other experiments point to 
iron release from transterrin located intracellularly in coated 
vesicles [16]. After this transferrin is recycled into the medium 
[16]. We therefore examined whether transferrin binding by 
erythroblasts could be impaired in ACD, resulting in reduced iron 
uptake. We found that transferrin binding was impaired in ACD compared 
to healthy controls whereas it tended to be decreased compared to 
nonanemic and iron deficient RA patients. It also tended to be reduced 
in the other RA groups compared to controls. So it might be speculated 
that impaired iron uptake by erythroblasts found in ACD is caused by 
decreased transferrin binding to the erythroblasts because this was 
significantly reduced in ACD, whereas in the other 2 RA groups it was 
only slightly reduced. It can also be argued that intracellular iron 
release from transferrin is reduced resulting in decreased iron 
availability for haemsynthesis. Iron retention by 
monocytesjmacrophages in the medium seems less probable because we do 
not expect these cells to influence transferrin binding by 
erythroblasts. It is not known whether transferrin receptor 
expression, its affinity at the erythroblast membrane surface or the 
number of transferrin receptors is reduced in ACD. Possibly in RA 
and/or ACD transferrin glycosylation is different [17]. This might 
result in a change of transferrin receptor affinity and iron binding 
[18,19]. In our experiments this was ruled out because the same 
transferrin was added to the medium in all groups. 
In summary, we found that iron uptake by erythroblasts was reduced 
in RA patients with ACD, and to a lesser extent in iron deficiency. 
Iron uptake correlated negatively with RA disease activity. 
Transferrin binding to erythroblasts was also reduced in ACD. We 
therefore conclude that an impaired iron uptake by erythroblasts, 
possibly due to a reduced transferrin binding by erythroblasts, might 
be a pathogenetical factor in ACD in RA. 

ClJAPTER 7 
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PART OOE. DEFECTIVE ERYTHROPOIETIN RESPamrvmESS TO THE ANEMIA IN 
RA PATIENI'S WITH ACD AND Ilm' DEFICIENCY 
7. 1.1 INTRODUCTION 
In Chapter 3 it was clearly shown that levels of parameters of RA 
disease activity like ESR, CRP and C1qba were higher in ACD patients 
compared to nonanemic RA patients. In Chapter 3 and 4 it was found that 
levels of these parameters were higher among ACD patients compared to 
iron deficient patients. The observation of a negative correlation 
between ESR, CRP and Hb found in Chapter 4 was also found by Birgegard 
et al. [1]. The mechanism through which an increased RA disease 
activity level determines the degree of anemia is unknown. Some authors 
found that interleukin-1 could be the factor involved [2], whereas 
others speculate on a role of tumor necrosis factor alpha [3]. 
A defective response of erythropoietin has also been claimed to play 
a role in ACD pathogenesis but the findings are controversial [4]. 
We examined a potential pathogenetic role of a decreased 
erythropoietin responsiveness to anemia in RA patients with ACD. 
7. I. 2 PATIENTS AND METHODS 
7.1.2.1 Patients 
Eighteen anemic RA patients (12 with ACD, 6 with iron deficiency, 2 
with coexistent vitamin B12 deficiency and 2 with coexistent folic acid 
deficiency) were studied. The 12 patients with ACD were the same as 
those with ACD in the study described in Chapter 3. The 6 iron 
deficient patients, who served as controls, consisted of a randomly 
taken subset of the iron deficient patients from the study described in 
Chapter 3. 
The same in- and exclusion criteria were used (see Chapter 3, page 
50). Patient characteristics including age, sex, disease duration and 
antirheumatic treatment used showed approximally the same distribution 
as described in Chapter 3 (page 50). 
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7.1.2.2 Laboratory procedures 
The following parameters described in Chapter 2 were assessed: 
Erythrocyte parameters 
Hb, Ht, reticulocyte count, M.CV, M.CH. 
Iron status 
Fe, iron, transferrin, ferritin. 
Vitamins 
Vitamin B12, folic acid. 
Disease activity 
ESR, CRP, C1qba, rose titer. 
Serum erythropoietin 
Bone marrow was aspirated after sternal puncture and stainable ):>one 
marrow iron was assessed. 
7. I. 3 RESULTS 
TABLE I Relationship between type of anemia, Hb·and serum erythro-
voietin (Epo). Data are expressed as median and range. 
Iron Acoll Low B122 > 
deficiencY- > 
Number 9 5 2 
Hb ( nunoljl ) 5.9 6.3 6.6 
(4.2-7.1) (5.4-7.1) (6.5-6.6) 
Epo (U/l) 60 15 25 
(10-420) (10-28) (20-30) 
ll Patients with low B12 or folic acid were excluded 
2
> One patient with iron deficiency, one with ACD 
3
> Both patients with iron deficiency 
Low folic 
acid3 > 
2 
6.4 
(5.8-7.0) 
20 
(10-80) 
Correlation of parameters of erythropoiesis, iron status, disease 
activity with serum Epo 
The erythrocyte parameters, iron status, disease activity, vitamin 
B12 and folic acid levels were comparable to the data shown in Chapter 
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3, Table 1. 
Serum Epo was assessed in 18 anemic patients (12 of them were iron 
deficient and 6 had ACD). It is shown in Table 1 that Epo level was 
higher in iron deficient patients compared to patients with ACD 
(p<0.02). In iron deficient patients 1 patient (8%) had a serum Epo 
below normal. One patient in the ACD group ( 17%) had a serum Epo below 
normal. No difference was found in Epo level between B12 deficient and 
non B12 deficient patients. 
deficiency patients (ns). 
Epo level was lower in folic acid 
I 
Epo level correlated negatively with Hb level (r=-0.6, p<0.005) but 
did not correlate with ESR, CRP or C1qba. It was found to correlate 
negatively with ferritin for the whole group (r=-0.45, p<0.05) but not 
in ACD alone. 
7. I. 4 DISCUSSION AND Sl:MMRY 
In this study we examined a potential pathogenetical role of a 
decreased Epo responsiveness in ACD in RA patients. 
Epo in most patients were higher than in healthy controls [5]. 
Obviously there is some response to the anemia in both ACD and iron 
deficiency. 
Epo level was significantly lower in patients with ACD compared to 
iron deficient patients while Hb did not differ significantly between 
these groups. These two types of anemia cannot be fully separated in RA 
patients as was described in Chapter 3 and 4 which might have decreased 
the difference in Epo level in these groups. Patients with low B12 or 
folic acid had lower Epo levels but they were equally distributed 
between iron deficient and ACD patients making interpretation of this 
finding difficult together with the low number of cases. A negative 
correlation was found between Hb and Epo, most pronounced in iron 
deficient patients. In both groups only 1 patient had a serum Epo below 
normal ( 8% among iron deficient and 17% in ACD patients) • Epo 
correlated negatively with ferritin. These findings suggest that the 
response to anemia caused by iron deficiency in RA is higher than to 
ACD. 
Baer [4] also found lower Epo levels in ACD in RA. Birgegard and 
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Erslev [1,6], however, found higher Epo levels in anemic RA patients 
than nonanemic controls irrespective of the cause of anemia. ACD in RA 
was associated with highest levels of ESR, CRP and Clqba (Chapter 3, 
Table 1). Epo was lowest in ACD although no correlation was found 
between ESR and Epo in contrast to Birgegard [1]. It might still be 
speculated that a factor, correlated with disease activity, has a 
restrictive effect upon Epo production. Since the number of patients 
investigated was small, further study is warranted in order to examine 
the relation of Epo and iron stores and to compare Epo response between 
anemic and nonanemic RA patients. 
In summary, we found that serum Epo was increased in anemic RA 
patients compared to healthy controls and that serum Epo was higher in 
iron deficient RA patients compared to those with ACD, whereas serum 
Epo correlation negatively with serum ferritin suggesting that Epo 
response to anemia .was higher in iron deficient patients. In both 
groups Epo response was insufficient to correct the anemia. 
PART 'l'l'l). ERYTHROPOIETIN RES:E'CNSIVENESS TO THE ANEMIA IN RA PATIENTS 
WITH ACD AND IR(Xq DEFICIENCY COMPARED TO ~C RA PATIENTS 
7. 2. I INTRODUCTION 
It was shown in the study described in part one of Chapter 7 that 
serum Epo was increased in both RA patients with ACD and iron 
deficiency compared to serum Epo levels in 30 healthy individuals. This 
rise in serum Epo obviously was insufficient to prevent anemia. In that 
study sera from nonanemic RA patients were not examined because of a 
limited availability of the assay. In comparing serum Epo from 
nonanemic and anemic RA patients Erslev [1,2] and Birgegard [3] found 
higher serum Epo levels in ACD whereas Baer [4] found lower levels in 
ACD. The role of a decreased Epo responsiveness in the pathogenesis of 
ACD is therefore not yet fully established. 
We found that serum Epo was higher among iron deficient RA patients 
compared to those with ACD (Chapter 7, Part one) while serum Epo level 
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correlated negatively with serum ferritin. 
This study was performed to compare Epa responsiveness between 
nonanemic and anemic RA patients in order to determine its potential 
role in ACD. The second aim was to confirm our earlier observations of 
increased Epa responsiveness in iron deficient patients compared to 
those with ACD. 
7.2.2 PATIENTS AND MEiffQDS 
7.2.2.1 Patients 
Thirty patients (6 male, 24 female) with definite or classical RA 
were studied after giving written informed consent. Patients who were 
treated with iron, vitamin B12 and folic acid were excluded. Other 
causes of anemia were excluded by history, serum vitamin B12 and folic 
acid assay, the presence of hematuria or positive occult blood test in 
stool, decreased creatinine clearance and the presence of hemolysis, 
low B12 or folic acid. Patients were divided into three groups. Group 
I: 11 nonanemic patients; Group II: 7 iron deficient patients; and 
group III: 12 patients with ACD. 
OVerall disease duration was 8.5 years (5.2-14.6), 72% were Rose 
positive and the majority of patients (73%) were treated with 
long-acting antirheumatic drugs and/or nonsteroidal anti-inflammatory 
drugs. Mean age was 59 years (32-71). These clinical data did not 
differ significantly between the three groups. 
7.2.2.2 Laboratory procedures 
The following parameters, described in Chapter 2, were assessed: 
Erythrocyte parameters 
Hb, Ht, reticulocyte count, MCV, MCH. 
Iron status 
Fe, iron, transferrin, ferritin. 
Disease activity 
ESR, CRP, C1qba, rose titer. 
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Serum erythropoietin 
Bone marrow aspirations (sternal puncture) were stained for iron 
content. 
7. 2. 3 RESULTS 
7.2.3.1 Relationship between erythrocyte parameters, parameters of 
disease activity and serum Epo 
MCV and MCH were significantly lower in Group II and tended to be 
lower in Group III compared to Group I (Table 1). 
ESR and CRP were significantly higher in Group III compared to Group 
I and II. 
Epo in Group I and Group III did not differ and in Group II it 
tended to be higher compared to Groups I and II (p<O.lO). 
Hb correlated negatively with ESR (r=-0.86); p<0.0005) and CRP 
(r=-0.39; p<0.05). In Group II these correlations were not significant. 
Epo correlated with neither erythrocyte parameters nor parameters of 
disease activity. 
7.2.3.2 Relationship between serological iron parameters and Epo 
Serum iron was significantly lower in Groups II and III compared to 
Group I (Table 2). 
Transferrin was significantly lower in Group III compared to Group 
I. 
Iron saturation was 
compared to Group I. 
significantly lower in Groups II and III 
Serum ferritin was significantly lower in Group II compared to 
Groups I and III. It was highest in Group III. 
Epo correlated negatively with serum ferritin in Group I (r=-0.57; 
p<0.025). No correlations were found ?etween Epo and other parameters 
of iron status. 
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Table 1 Relationship between erythrocyte parameters, parameters of 
disease activity and serum Epo in group I (nonanemics), group 
II (iron deficiency) and group Ill (ACD). Data are expressed 
as median with range. 
I II III 
n=11 n=7 n=12 
Hb 8.0 6.6 6.4 
(nuno1/1) (7.5-8.7) (6.2-7.2) (5.7-7.2) 
MCV 91 87 87 
(f1) (80-102) (74-90) (78-110) 
MCH 1920 1770 1800 
(amol) (1560-2070) (1400-1860) (1530-2390) 
r5ticulocytes 15 20 18 
( /00) (5-39) (6-30) (5-41) 
ESR 37 59 85 ( lliill/h) (21-60) (14-105) (34-102) 
CRP 9 9 38 
(mg/1) (4-45) (2-57) (10-74) 
Epo 41 50 43 
(mU/ml) (24-92) (23-96) (32-89) 
Table 2 Serological parameters of iron status in group I (nonanemics), 
group II (iron deficiency) and group Ill (ACD). Data are 
expressed as median with range. 
I II III 
n=ll n=7 n=12 
iron 11 5 6 
pmol/1 (5-17) (3-7) (9-11) 
transferrin 63 56 49 
.umol/1 (47-78) (51-64) (39-67) 
iron saturation 16 9 10 
% (8-31) (5-11) (4-22) 
ferritin 42 20 91 
(pg/1) (18-142) (10-24) (36-273) 
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7.2.4 DISCUSSION AND S~Y 
In this study we evaluated Epo response in anemic and nonanemic RA 
patients as well as the difference in Epo response between RA patients 
with iron deficiency and ACD. 
Hb correlated negatively with parameters of disease activity (ESR 
and CRP) suggesting that, especially in ACD, RA activity dictates Hb 
level. This negative correlation was also found in previous chapters. 
Many theories exist to explain this correlation. Inhibition at stem 
cell level is claimed to play a role [5]. Interleukin-1 (IL-l) was able 
to suppress erythroid colony growth in vitro while serum IL-l levels 
were higher in RA patients with ACD [6]. 
Serum Epo was determined using a sensitive radioimmunoassay [7]. The 
assay used in part one was different, so data of part one and two could 
not be combined. Furthermore in part one the availability of the assay 
was limited restricting the number of sera for Epo assessment. 
In this study it was shown that serum Epo level was the same in 
nonanemics and ACD patients. It did not correlate with Hb level. Epo 
level was higher than in 30 healthy donors (22 ± 4 mU/ml). This 
suggests that in nonanemic RA patients an Epo rise effectively 
prevented development of anemia. Obviously when RA activity rises 
resulting in development of ACD, in which RA activity was found to be 
highest, Epo response is insufficient. In the previous study (Chapter 
7, Part one) we did find a correlation with Hb and Epo in RA but more 
pronounced in iron deficiency than in ACD. We therefore concluded that 
some Epo response exists in RA and ACD but it is less prominent than in 
anemia of other etiology. Another possibility could be that bone marrow 
Epo sensitivity is impaired in RA and ACD but this cannot be concluded 
from these data. In vitro studies are necessary to demonstrate this 
phenomenon. 
Epo was higher in iron deficient RA patients. The difference in Epo 
between these patients and patients without anemia or ACD is probably a 
little masked since these patients also have a certain level of disease 
activity resulting in features of ACD (Chapter 3 and 4). In the 
previous study (Chapter 7, Part one) Epo response in iron deficient RA 
patients was significantly higher compared to those with ACD. This was 
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supported here by the finding of a negative correlation between Epo and 
serum ferritin in nonanemics. These patients have a low degree of 
disease activity and therefore serum ferritin determines iron stores 
[8,9]. In Groups II and III serum ferritin levels reflect levels of 
disease activity more since it behaves like a positive acute phase 
reactant (Chapter 3, 4), so its relation with iron stores is less clear 
explaining the finding of only a weak negative correlation between Epo 
and serum ferritin in ACD. In our previous study (Chapter 7, Part one) 
the correlation between ferritin and Epo existed if all 18 subjects 
were considered together, but in ACD and iron deficiency separately the 
correlation was absent. In ACD associated with the highest degree of RA 
activity, serum Epo.tended to be lower than in iron deficiency possibly 
due to mechanisms related to RA activity [3]. However, ESR was higher 
in iron deficiency compared to nonanemics while Epo was higher as well. 
This might point to a specific relation of Epo and iron status. 
In summary, it was shown that in RA patients with or without anemia 
serum Epo is increased compared to healthy volunteers. In nonanemic RA 
patients this rise in Epo prevented development of anemia whereas in 
ACD - associated with a higher degree of disease activity - Epo 
response does not further increase and is therefore insufficient. In 
iron deficiency, with the same Hb level as in ACD, serum Epo tended to 
be higher. we conclude that a defective Epo response to anemia might 
play a pathogenetic role in ACD and Epo response might be negatively 
correlated with iron stores. 
CHAPTER 8 
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THE EFFECT OF TRFATMENT WITH THE ORAL I~ QIELATOR 1,2-DIMETHYir-3-
HYDROXYPYRID-4---<:m: 00' ERYTHROPOIESIS AND SERUM EP0 
8. I INTRODUCTION 
As was demonstrated in the study described in Chapter 6 iron uptake by 
erythroblasts and transferrin binding to erythroblasts is defective in 
ACD. Others examined ineffective iron turnover by erythroblasts in 
vitro and found it to be increased suggesting that iron release by 
erythroblasts is increased [1]. Other work points to a possible 
defective iron release by the MPS in case of ACD although this is 
controversial [2,3]. In both theories a decrease in iron availability 
for erythroblasts is supposed to be of pathogenetical importance in the 
development of ACD. Iron administration to RA patients with ACD for 6 
weeks did not result in increased erythropoiesis suggesting that bone 
marrow iron availability does not increase in this way (Chapter 5). 
Another observation was the possible defective Epo responsiveness to 
anemia in ACD whereas it was shown that in iron deficient RA patients 
Epo response was higher than ACD with the same degree of anemia 
suggesting a negative correlation of Epo response with iron stores 
(Chapter 7, Parts one and two). The use of desferrioxamine, a 
parenteral iron chelator was associated with a decrease in RA disease 
activity [4] and a Hb increase [5]. Recently an oral iron chelator, 
1,2-dimethyl-3-hydroxypyrid-4-one (Ll) was used successfully in thalas-
semia and transfusion hemosiderosis [6,7] and it was shown by Mostert 
et al. [8] not to be cytotoxic. 
This study was performed to examine whether iron release from iron 
stores by oral iron chelation in RA patients with ACD results in 
increased erythropoiesis and Epo responsiveness to the anemia. 
8. 2 PATIENTS AND MElliODS 
8. 2. I Patients 
Ten RA patients (2 male) with ACD fitting Cartwright's criteria 
[9,10] (2 male) were randomly selected from a group of 12 RA patients 
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with ACD from the study described in Chapter 7, Part two. Patients 
treated with iron, vitamin B12 and folic acid were excluded. Other 
cases of anemia were excluded by history, serum vitamin Bl2 and folic 
acid assay, the presence of hematuria or positive occult blood test in 
decreased creatinin clearance and the presence of hemolysis (Coombs, 
haptoglobin). 
OVerall disease duration was 9.2 years (5.2-18.3), 65% were Rose 
positive, whereas 79% used long-acting antirheumatic drugs andjor 
nonsteroidal anti-inflammatory drugs. Mean age was 62 years. 
8.2.2 Treatment with Ll 
11 was prepared as previously described [11] in gelatin capsules 
(0.5 g) and administered 1-2 hours before meals. Its structural formula 
is shown in Fig.1. The patients were treated for 1 week according to a 
protocol for use in RA patients (G.J. Kontoghiorghes; unpublished). At 
day 1, 2 g once a day, at day 2, 2 g in the morning and 1 g in the 
afternoon and from day 3 on 2 g twice daily were administered. 
FIGURE I Structural formula of 1,2-dimethyl-3-hydroxypyrid-4-one (Ll) 
0 
OH 
Tab I e I Erythrocyte parameters, serum Epa and parameters of disease activity before and after I week 
Ll treatment. 
Hb Ht retics MCV MCH Epa ESR CRP 
mmol/1 (0/00) (fl) (arnol) mU/ml mm;h (mgjl) 
before 6.0 0.30 18 87 1770 39 87 32 
(5.7-7.0) (0.28- (5-41) (78-104) (1530-2150) (21-67) (22-102) (4-70) I-' 
0 
0.35) co I 
after 6.5+ 0.32 22 88 1830 49+ 84 17 
(4.9-7.5) (0.23- (5-44) (79-111) (1550-2310) (23-95) (22-118) (4-74) 
0.36) 
+ p<0.10. Data are expressed as median with range. 
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8.2.3 Laboratory procedures 
The following parameters, described in Chapter 2, were assessed: 
Erythrocyte parameters 
Hb, Ht, MCV, MCH, reticulocytes. 
Iron status 
serum iron, transferrin, iron saturation (serum iron/transferrin), 
ferritin, urine iron excretion. 
Disease activity 
ESR, CRP. 
Serum Epo 
Bone marrow aspirations (sternal puncture) were stained for iron 
content. 
All parameters, except bone marrow aspiration, were repeated after 1 
week of treatment. 
Table 2 Serological iron status before and after I week of Ll treatment 
(s-iron is serum iron, u-iron is urine iron excretion in 24 h). 
s-iron transferrin iron saturation ferritin u-iron 
(p:mol/1) (p:mol/1) % (pg/1) (pmol/24h) 
before 6 51 11 91 0.5 
(2-11) (39-67) (4-21) (20-279) (0.4-0.8) 
* * * after 14 61 24 50 4.4 
(7-34) (39-76) (15-45) (15-319) (0.5-14.6) 
*p<O.Ol. Data are expressed as median with range. 
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Table 3 Correlation between changes (~) in Hb, Epo, ESR, CRP 
and iron status after Ll treatment of ACD patients 
Parameters r p 
~Hb - ~ Epo 0.66 0.05 
~Hb - ~ ESR -0.76 0.01 
~Hb - ~ CRP -0.62 ns 
~Hb - ~ iron saturation 0.53 0.05 
~Hb - ~ ferritin -0.78 0.01 
~ Epo- ~ ESR -0.34 ns 
~ Epo- ~ CRP -0.31 ns 
~ Epo- ~ ferritin -0.76 0.025 
~ Epo- ~iron -0.48 ns 
~ Epo - ~ iron saturation -0.31 ns 
~ Epo - ~ retics 0.48 ns 
Ten paired data were analyzed. In case of CRP only 8 paired 
data were compared. 
8. 3 RESULTS 
8.3.1 The effect of LI iron chelation on erythropoiesis. disease 
activity and serum Epo 
Hb increased in these 10 patients by 0.5 mmoljl (p<0.10). The 
response rate was 70%. Among responders the increase was 0. 7 mmol/1 
(p<0.02) (Table 1). 
Serum Epo increased nearly significant (p<0.10). A positive 
correlation was found between changes in Hb and Epo. Changes in ESR and 
Hb were correlated negatively (Table 3), although ESR did not change 
significantly. 
8.3.2 The effect of Ll iron chelation on serum iron status and urine 
iron excretion 
Serum iron, transferrin, iron saturation and urine iron excretion 
(in 24 h) increased significantly while a decrease in serum ferritin 
was found (Table 2) • 
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Changes in Epo were negatively correlated with changes in serum 
ferritin (Table 3). 
Hb increase was negatively correlated with serum ferritin change. 
8.3.3 Tolerance toLl 
No serious adverse reactions were seen in 10 patients treated with 
Ll. Two patients had transient nausea (1 day). Endoscopic examination 
revealed no abnormalities. No changes were found in creatinin 
clearance, serum bilirubin, alkaline phosphatase, ASAT, ALAT and 
gamma-GT. 
8.4 DISCUSSION 
We examined whether iron release from iron stores in RA patients 
with ACD results in increased erythropoiesis and serum Epo. Ll was 
shown to be an effective oral iron chelating agent in RA patients with 
ACD. After 1 week serum iron, transferrin, iron saturation and urine 
iron excretion increased significantly while serum ferritin decreased. 
These findings confirm that in ACD in RA patients iron stores are 
increased [9,10 and Chapters 3, 4 and 5]. The drug was well tolerated 
with only little transient nausea occurring in 2 patients. In this 
limited number of patients and short period of treatment no obvious 
signs of toxicity occurred. 
Hb increased in 70% of patients by 
treatment (0.5 mmol/1 for the whole group). 
with serum ferritin decrease and increase 
0.7 mmol/1 after 1 week of 
The increase correlated 
of iron saturation. It is 
suggested that a decreased bone marrow iron availability due to a 
diminished iron release by the mononuclear phagocyte system (MPS) 
related to RA disease activity results in development of ACD [2,3]. We 
therefore believe that bone marrow iron availability is increased 
through a higher serum iron and iron saturation of transferrin after 
release of iron from the MPS and ferritin by Ll and its exchange with 
transferrin [12-14]. In the study described in Chapter 6 we found that 
iron uptake by and transferrin binding to erythroblasts was decreased 
in RA patients with ACD compared to those without anemia, iron 
deficiency and healthy controls. Since Hb increased this may very well 
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fit the concept that transferrin receptor expression on erythroblasts 
is increased by iron chelators resulting in more efficient iron uptake 
which was found by Louache et al. [15]. 
An increase in serum Epo was observed which was correlated 
positively with a Hb rise. If serum Epo change had not been related to 
treatment we would rather have expected a decrease in Epo as a Hb 
increase as such might diminish Epo demand. Hb and Epo changes 
correlated negatively with serum ferritin changes. Together with a 
higher Epo in iron deficient RA patients (Chapter 7, Parts one and two) 
these findings suggest that Epo response indeed is negatively 
correlated with iron stores. Others also found higher Epo levels in 
iron deficient RA patients [16] while Hb level did not differ from that 
in ACD. So the Hb increase following Ll treatment might not only be 
explained by factors described before but also by increased Epo 
response to the anemia. It is not known what causes the increased Epo 
response to the anemia after iron release. Rich et al [17] showed that 
Epo production occurs in bone marrow by macrophages and monocytes. The 
Epo production in bone marrow is dependent on local pH and oxygen 
tension [18,19]. Possibly Epo production or Epo gene expression by 
marrow macrophages increases when the increased iron stores in these 
cells are diminished but this is highly speculative. It was shown that 
in hemodialysis patients a Hb rise following desferrioxamine treatment 
occurred [19,20] but in this study it was not shown whether Epo 
response increased, although this is less probable because of 
insufficient renal production. In another study after prolonged 
desferrioxamine treatment in RA patients Hb decreased, but in this 
study baseline serum ferritin was low in most patients, suggesting iron 
deficiency, while Epo levels were not assessed [21]. 
Parameters of disease activity did not decrease significantly, 
although Hb rise correlated with ESR decrease suggesting that Ll 
treatment reduced RA activity resulting in a Hb rise. The period of 
treatment was too short for evaluation of effects of Ll on RA activity 
(both serologically and clinically), however. 
Other studies point to a beneficial effect on RA activity using 
desferrioxamine as iron chelator [4,22]. Future studies with prolonged 
Ll treatment will possibly give further evidence for this effect. 
- 113-
In summary, we demonstrated that the administration of the oral iron 
chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) effectively chelated 
iron from iron stores. A Hb rise, seen in 70% of patients, correlated 
with a rise in serum Epo. After L1 treatment serum ferritin decrease 
correlated negatively with a Hb and Epo increase. These findings 
confirm our earlier observations of an increased Epo response in 
patients with lower iron stores. Iron release from iron stores might 
increase erythropoiesis in ACD through increased bone marrow iron 
availability, increased iron uptake and transferrin binding to 
erythroblasts or through increased Epo response to the anemia. Further 
study is warranted to establish the preliminary findings of increased 
erythropoiesis after iron chelation as well as safety of L1. 

CHAPTER 9 
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'lHE ROLE OF 'l'(][tJJR NECROSIS FACTOR ALPHA IN ANEMIA OF CHRCMIC DISFASE IN 
RA PATIENTS: ELEVATED SERUM LEVELS AND IN VITRO SUPPRESSIOO OF 
ERYTHROPOIESIS 
9. I INTRODUCTION 
In all studies described before we clearly found a negative 
correlation between parameters of RA disease activity like ESR, CRP and 
C1qba with Hb, especially among the RA patients with ACD. Levels of 
these parameters were higher in ACD compared to nonanemic and iron 
deficient patients. We found that iron incorporation into and 
transferrin binding'by erythroblasts to be decreased in ACD while in 
iron deficient RA patients these were also slightly reduced (Chapter 
6) • It was also demonstrated that Epo response to anemia was 
insufficient, levels being the same in nonanemic RA patients and those 
with ACD while in RA patients with iron deficiency the response tended 
to be higher (Chapter 7, part one and two). Although these factors 
might contribute to the pathogenesis of ACD we searched for other 
possible factors which are related to RA disease activity and immune 
response and may act on erythropoiesis. 
Interleukin-1, a cytokine produced by monocytes, was able to 
suppress in vitro erythropoiesis [1,2]. Tumor necrosis factor alpha 
(TNFa), another cytokine, which is frequently elevated in serum of 
patients with active disease [3,4] might also have a pathogenetic role 
in RA [5]. The effects of TNFa on erythropoiesis are uncertain [1,6,7]. 
We therefore studied the possible pathogenic role of TNFa in 
determining ACD in RA patients. 
9.2 PATIENTS AND MElliODS 
9.2.1 Patients 
Bone marrow from 33 patients with definite or classical RA [8] and 6 
normal donors were studied after giving written informed consent: Group 
I (n=6) consisted of bone marrow transplantation donors (considered as 
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healthy controls). Group II (n=11) consisted of nonanemic RA patients, 
group III consisted of RA patients with ACD (n=13) (for definition see 
under "Laboratory procedures") and group IV consisted of RA patients 
with iron deficiency (n=9). 
Patients who had iron, vitamin B12 or folic acid treatment recently 
or patients with a present or past ulcer history, hematuria, 
hypermenorrhoea, positive occult fecal blood test, hemolysis, vitamin 
B12 or folic acid deficiency o~ decreased creatinin clearance were 
excluded. From the RA patients 7 were male. Overall disease duration 
had been 8 years (range: 3-18), 71% used long-acting antirheumatic 
drugs (patients using corticosteroids or cytostatic drugs were also 
excluded) and 82% used nonsteroidal anti-inflammatory drugs. Mean age 
was 62 years. These characteristics did not differ in the three RA 
groups. 
9.2.2 Laboratory procedures 
The following parameters, described in Chapter 2, were assessed: 
Erythrocyte parameters 
Hb, Ht, reticulocyte count. 
Iron status 
Serum iron, transferrin and ferritin. 
Disease activity 
ESR, CRP, C1qba, Rose titer. 
Serum TNFa. 
Bone marrow aspirate (posterior superior iliac crest puncture) was 
stained for iron content. Twenty milliliter of aspirate was used for 
culturing erythroblasts. BFUe was used as parameter for erythropoiesis 
(Chapter 2.9.2). 
In group I (n=6), II (n=S), III (n=7) and IV (n=6) TNFa. (Boehringer 
Institute, Vienna, Austria) 100 U/ml, TNFa. 1000 U/ml and anti-TNFa. 
(Boehringer Institute, Vienna, Austria) 1000 U/ml, respectively, were 
added to the BFUe cultures to evaluate their effects on in vitro 
erythropoiesis. 
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TABLE I Erythrocyte parameters, BFUe count, parameters of RA disease 
activity and TNF in healthy controls and RA patients without 
and with anemia (ACD or iron deficiency). Values expressed as 
median with range. 
I 
controls 
(n=6) 
Hb 8.1 
(mmol/1) (7.7-8.2) 
Ht 0.40 
(L/L) (0.37-0.40) 
Reticulocytes 16 
(0/00) (3-21) 
BFUe count 346 
(per 105 cells) (84-396) 
ESR 21 
(MM/h) (16-26) 
CRP 4 
(mgjL) (2-6) 
C1qba 3 
(%) (3-4) 
Rose+ 0 
TNF 7 
(pg/ml) 
+ Reciprocal Rose titre 
II 
nonanemicjRA 
(n=ll) 
8.0 
(7.7-8.7) 
0.38 
(0.35-0.42) 
10 
(1-39) 
305 
(215-391) 
36 
(21-65) 
22 
(2-54) 
5 
(3-32) 
64 
(0-512) 
13 
(9-28) 
III 
ACD/RA 
(n=13) 
6.4 
(5.7-7.2) 
0.31 
(0.28-0.36) 
17 
(1-30) 
189 
(12-308) 
76 
(34-105) 
63 
(10-101) 
14 
(4-75) 
16 
(0-256) 
28 
(13-93) 
IV 
iron def.jRA 
(n=9) 
6.5 
(4.3-7.1) 
0.34 
(0.24-0.37) 
12 
(1-26) 
179 
(58-440) 
62 
(32-111) 
22 
(2-78) 
13 
(3-78) 
48 
(0-512) 
14 
(6-28) 
TABLE 2 Serological parameters of iron stat us in heal thy controls and 
RA patients without and with anemia (ACD or iron deficiency). 
Values expressed as median with range 
Fe 
(pmol/1) 
Transferrin 
(pmol/1) 
Ferritin 
(pg/1) 
Controls 
(n=6) 
13 
(12-14) 
52 
(50-59) 
22 
(10-34) 
nonanemicjRA 
(n=ll) 
8 
(1-15) 
56 
(40-78) 
33 
(10-326) 
ACDjRA 
(n=13) 
4 
(2-11) 
46 
(39-60) 
125 
(28-432) 
iron def.jRA 
(n=9) 
5 
(2-10) 
60 
(52-81) 
13 
(10-53) 
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9. 3 RESULTS 
9.3./ Parameters of erythropoiesis, disease activity and serum TNFa. in 
controls, nonanemic and anemic RA patients (Table I) 
Erythropoiesis. Hb and Ht did not differ between group III and IV 
(Table 1). Reticulocyte count did not differ significantly between the 
4 groups. Hb correlated negatively with ESR and serum TNF (Fig. 1) and 
CRP (r=-0.44;p<0.025) and Clqba (r=-0.46;p<O.Ol) but not with Rose 
titer (groups I, II and III). BFUe counts were lower in group III 
compared to I (p<0.05) and II (p<0.05). They were also decreased in 
group IV compared to I (p<0.05). BFUe counts tended to be reduced in 
group II compared to I. The BFUe values correlated positively with Hb 
(r=0.36; p<0,05). Negative correlations were apparent between BFUe 
count and ESR (Fig. 1) but not with CRP, Clqba and serum TNF. 
Disease activity. ESR, CRP and Clqba were higher in ACD compared to 
nonanemics (pat least< 0.05). ESR and CRP were higher in III compared 
to IV (p<O.lO and 0.05, respectively). Rose titer did not differ 
significantly between the 4 groups. 
Serum TNFa.was higher in group III compared to group II (p<0.02) and 
group IV (p<O.lO). It correlated positively with ESR (r=0.55, p<0.02), 
CRP (r=0.43, p<0.05) and Clqba (r=0.41, p<0.05). 
FIGURE I Correlation between ESR and Hb, ESR and BFUe count and serum 
TNFa. and Hb level. Only data available from nonanemic RA 
patients and RA patients with ACD were used in order to avoid 
complicating factors involved (non-RA controls, iron 
deficiency). 
ESR/BFUe : r- -0.66 (P<O.OOS) 
TNFo:/Hb : r• -0.55 lP<0.01l 
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TABLE 3 Effects of the addition of TNFrx and anti-TNFrx antibody on erythroid growth from bone marrow in the 
four groups. 
I II III IV 
Addition to controls non-anemic/RA ACD/RA Fe def.jRA 
cultures n=6 n=5 n=7 n=6 
abs % abs % abs % abs % 
None 346 100 246 100 150 100 189 100 
(92-396) (239-349) (12-280) (58-440) 
287+ 82+7 ** 191** 71+27** 86+ 57+zo** 81+12** 'INFrx 171 
(100 U/ml) (66-348) (71-89) (98-244) (35-99) (2-195) (17-78) (98-441) (65-100) 
zz** 10+7 ** o** ** 9** 8+6** a** 2+2** 'INFrx 4+5 
(1000 U/ml) (2-75) (2=19) (0-29) (0-12) (0-54) (0-19) (5-22) (l-6) 
anti-'INFrx 394 145+51+ 418+ 136+29* zoo+ 154+70+ 208 127+15** 
(1000 U/ml) (238-579) (105-257) (218-469) (90=180) (37-300) (90=308) (70-641) (98=146) 
+ * ** p<O.lO, p<0.05, p<O.Ol (compare~ to cultures with no addition) 
Values indicate numbers of BFUe per 10 cells (median; range). Relative values (control set at 100%) are 
expressed as mean with standard deviation. 
..... 
N 
0 
I 
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9.3.2 Correlation of iron status with parameters of erythropoiesis and 
disease activity and TNF~ (Table 2) 
Serum iron correlated positively with BFUe count (r=0.63, p<0.025) 
and negatively with serum TNF (r=-0.40, p<O.OS), ESR (r=-0.38, p<O.OS) 
and CRP (r=-0.36, p<O.lO) in group III. Transferrin correlated 
positively with BFUe in groups II and III (r=0.38; p<O.OS) and 
negatively with serum TNF (r=-0.53; p<O.Ol). Ferritin correlated 
positively with ESR (r=0.42, p<0.025), CRP (r=0.57, p<O.OOS) and serum 
TNF (r=0.38, p<O.OS) but not with BFUe count. 
9.3.3 Effects of addition of TNF~ and anti-TNF~ to bone marrow cultures 
(Table 3, Fig. 2) 
FIGURE 2 The effect of addition of anti-TNF~ and two concentrations of 
TNF~ to BFUe cultures. Control-set is 100% in cultures with 
no addition (BFUe standard) in controls, nonanemic RA 
patients and RA patients with ACD or iron deficiency. 
% 
200 
180 
160 
140 
Controls 
n=6 
non-an.IRA 
n=S 
ACD/RA 
n=6 
Fedef./RA 
n=6 
120 
100~~~~-------+----~-=r-----~--~.-~----+--r~~-r----~ 
80 
60 
40 
20 
o-L~--~-r~~~~~~~~~--~-r~~~~~--~-r~~ 
2 3 4 
1 = anti-TNFa 1000 U/ml 
2= BFUe count standard 
2 3 4 2 3 4 
3= TNFa 100 U/ml 
4= TNFa 1000 U/ml 
2 3 4 
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The addition of TNF~ at a concentration of 100 U/ml significantly 
inhibited erythroid colony growth in group II (p<0.02) and slightly in 
III (p<O.lO). Relative inhibition by 100 U/ml TNF~ occurred in all 
groups, most pronounced in group III compared to group I (p<0.05) and 
group IV (p<O.lO). A concentration of 1000 U/ml of TNF~ inhibited 
growth in all groups. 
The addition of anti-TNF~ (100 U/ml) resulted in stimulation of 
erythroid growth in groups II and IV. 
tendency was noted. 
9. 4 DISCUSSION AND SUIM-tRY 
In group I and III the same 
In this study we examined a potential pathogenetic role of TNF~ in 
determining ACD in RA. 
9.4.1 Erythroid colony growth, parameters of disease activity and iron 
status 
An inverse relationship is apparent between Hb and parameters of RA 
activity, i.e. ESR, CRP and Clqba while these parameters were highest 
in ACD, confirming earlier findings in Chapter 3-5. Erythroid colony 
growth is impaired in RA patients with ACD and not in nonanemic RA 
patients. BFUe count correlated positively with Hb and negatively with 
ESR. Based on the experimental data we assume that inhibition of 
erythropoiesis of ACD in RA and the degree of inhibition is determined 
by RA disease activity. Others only found slight differences in BFUe 
count between RA patients with and without ACD [9,10], mainly because 
these studies lack sufficient numbers of bone marrows investigated. 
ACD is associated with RA and several other chronic diseases. 
Harvey [9] found that BFUe count (from peripheral blood) correlated 
negatively with rheumatoid factor levels. We did not find this 
correlation confirming data from a previous study that rheumatoid 
factor plays no specific role in ACD pathogenesis (Chapter 3). 
Iron metabolism has been studied extensively in ACD. It has been 
postulated that decreased iron availability to erythroblasts might be 
caused by decreased iron release by the mononuclear phagocyte system, 
but the idea is still controversial [11,12]. In Chapter 6 we found that 
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iron uptake and transferrin binding by erythroblasts was impaired in RA 
patients with ACD and to a lesser extent in iron deficiency. Because of 
this we included bone marrow of iron deficient anemic RA patients as an 
additional group since in the latter iron availability to marrow 
precursors is unequivocally decreased. BFUe growth was decreased to the 
same extent in iron deficient RA cases as in ACD. Although transferrin 
bound iron is added to the marrow cultures this amount obviously is not 
sufficient for erythroblasts from iron deficient patients. It seems, 
however, most likely that -in view of a higher RA disease activity 
level compared to nonanemics- also in these patients erythroid growth 
mainly is restricted by RA activity. In Chapter 6 we found that reduced 
iron uptake may be of pathogenetical value in the development of ACD. 
In this study the in vitro model does not provide information whether 
iron uptake by or iron availability to bone marrow cells is decreased 
in ACD. Based on data presented in Chapter 8 (increase in 
erythropoiesis after iron release) we believe this is the case and 
further evidence in s~pport of a role of decreased iron availability 
comes from the fact that serum iron and transferrin correlated 
positively with BFUe numbers in RA patients with and without ACD. 
Transferrin is generally low and ferritin synthesis is augmented in 
active disease, resulting in iron trapping, hypoferremia and hence a 
lower iron transport to bone marrow [13,14]. Ferritin levels correlated 
positively with ESR, CRP and C1qba, confirming its acute phase behavior 
in active RA. No correlation of ferritin with Hb or BFUe marrow 
concentrates was found, however. Probably iron availability for marrow 
precursors does not further decrease after a certain level of ferritin 
synthesis, and hence iron entrapment, is reached. This might mask a 
potential negative correlation of ferritin with Hb and BFUe count. 
9.4.2 TNF~ and erythropoiesis 
Another factor associated with disease activity, TNF~, formerly 
designated cachectin [3,4], is mainly produced by monocytes and 
macrophages [15] and may have a role in the pathogenesis of RA. One of 
the biological effects of TNF~ is its ability to induce resorption of 
proteoglycan and inhibition proteoglycan analysis in cartilage [5] and 
it may therefore be of pathogenetical value in RA. TNF~ levels have 
been shown to be elevated in synovial fluid from RA patients [16]. 
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The results of this study show a positive correlation of serum TNF~ 
with ESR, CRP and Clqba. This may suggest that TNF~ may serve as a 
marker of disease activity in RA. 
In the group with RA and ACD serum concentrations of TNF~ were 
significantly higher than in the other groups. Hb correlated negatively 
with serum TNF. Of course these findings reflect increased disease 
activity of the ACD group. Elevated TNF~ serum levels in ACD have -to 
our knowledge- not been described previously. A negative correlation 
between BFUe count and serum TNF did not appear, but it is not unlikely 
that this could be due to the wide variation in both parameters. In the 
iron deficient group serum TNF~ level was similar as in nonanemics, 
suggesting that in these patients decreased iron stores contribute to 
the development of anemia. 
In order to verify the potential pathogenetic role of TNF~ in RA 
with ACD we added TNF~ to the marrow cultures. Indeed TNF~ exerted 
strongly and dose dependent suppressive effects on erythroid colony 
growth in controls, nonanemic RA patients, RA/ACD patients and iron 
deficient anemic RA patients. The relative inhibition by 100 U/rnl TNF~ 
was highest in the ACD group, suggesting increased susceptibility to 
TNF~. Lu [7] also demonstrated a suppressive effect on erythropoiesis 
by TNF~ in serum free medium. 
These observations suggest that a higher serum TNF~ not only 
reflects disease activity but also that TNF~ might play an important 
role in the pathogenesis of ACD in RA. ' 
Several theories exist to explain the effects of TNF~ on 
erythropoiesis. Possibly TNF~ addition induces IL-l production by 
monocytes [17], resulting in suppression of erythropoiesis [2]. Another 
possibility is a direct effect on CFUe and BFUe [6]. TNF~ is able to 
decrease protein synthesis [18] and may theoretically inhibit Epo 
synthesis since Epo response to the anemia is insufficient in RA and 
ACD (Chapter 7). It might also be that TNF~ reduces sensitivity of 
erythroblasts to Epo. Since IL-l synthesis results in hypoferremia [19] 
while the secretion of IL-l might be augmented by TNF addition [17]. 
Bone marrow iron availability could therefore be decreased by TNF~ 
since we found that serum TNF~ correlated negatively with serum iron 
and transferrin and positively with ferritin. Another speculation would 
be that TNF~ might cause reduced iron uptake by and transferrin binding 
to erythroblasts which was found to be associated with ACD (Chapter 6). 
- 125-
To study whether endogenous TNF production by marrow cells 
contributes to the findings of decreased erythroid colony amounts in 
ACD anti-TNF~ was added to the cultures. Indeed anti-TNF~ upregulated 
colony growth but the effects were similar in all 4 patient groups. 
This confirms endogenous negative effects of TNF~ produced by certain 
marrow cells in the medium but the phenomenon of TNF suppression did 
not differ among the 4 groups. It is suggested that a higher level of 
TNF~ and subsequent marrow suppression in RA patients with ACD was not 
due to a higher production of TNF~ by the marrow but in other sites, 
e.g., inflammatory sites such as the synovial membrane [16]. 
In summary, it was demonstrated that erythroid colony growth was 
reduced in RA patients with ACD. Since BFUe count correlated negatively 
with ESR it is suggested that RA disease activity affects erythroid 
colony growth in these RA patients. BFUe count was also reduced in .iron 
deficient RA patients and since these patients had intermediate RA 
activity it was concluded that decreased iron stores was another 
important factor involved in these patients. Based on earlier studies 
(Chapter 6) we believe this or decreased iron uptake by erythroblasts 
may also play a role in ACD. 
TNF~was found to correlate with parameters or disease activity and 
it correlated negatively with Hb but not with BFUe count possibly due 
to the wide variation in both parameters. It was significantly higher 
among RA patients with ACD. TNF~ was able to supp~ess erythroid colony 
growth in vitro confirming a potential pathogenetic role in ACD. 
Anti-TNF~ addition resulted in stimulation of erythroid colony growth 
suggesting that marrow cells in culture produce TNF~. The stimulatory 
effects of anti-TNF~were equal in all 4 categories suggesting that in 
vivo the effects of TNF~ are attributable to TNF~_production in other 
sites such as the joint and not to TNF~ production in marrow cells. 

CHAPTER 10 
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ANEMIA OF CHRCm:C DISFASE IN RHEUMATOID ARTHRITIS. RAISED SERUM 
INTERLEUKIN-6 (II.r-6) LEVELS AND EFFECTS OF IL-6 AND ANTI-IL-6 CN IN 
VITRO ERYTHROPOIESIS 
I 0. I INTRODUCTION 
In Chapters 7-9 we studied the role of hematopoietic growth 
factors Epo and TNFa. in the pathogenesis of ACD. Epo responsiveness to 
the anemia was shown to be reduced (Chapters 7 and 8) . Bone marrow Epo 
sensitivity could also be impaired (Chapter 9). TNFa. might have a 
pathogenetic role in RA [1]. we found that serum TNFa.was elevated in 
RA patients with ACD while it inhibited erythropoiesis in vitro 
(Chapter 9). 
Another interleukin, IL-6, is a monokine with biological 
activities related to inflammatory responses [2,3]. IL-6 levels were 
elevated in serum and synovial fluid of patients with active RA [4,5]. 
About the effects of IL-6 on bone marrow only few data exist [6]. 
We examined a possible role of IL-6 in the pathogenesis of ACD by 
comparing serum IL-6 levels and in vitro effects of IL-6 on erythroid 
progenitor cells in nonanemic RA patients, RA patients with ACD and 
healthy subjects. 
I 0. 2 PA Tl ENTS AND METIIODS 
I0.2.I Patients 
Bone marrow from 16 and serum from 21 patients (6 male, 15 female) 
with classical or definite RA and 5 normal donors were studied after 
patients' written informed consent. RA patients were divided into 2 
groups: Group I consisted of 9 nonanemic patients and group II of 12 
patients with ACD. Patients who had iron, vitamin B12 or folic acid 
treatment recently or patients with a present or past ulcer history, 
hematuria, menorrhagia, positive occult fecal blood test, 
hemolysis, iron, vitamin B12 or folic acid deficiency or decreased 
creatinin clearance were excluded. Patients using corticosteroids or 
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cytostatic drugs were also excluded. Overall disease duration had been 
7 years [4-17], 74% used long acting antirheumatic drugs and 88% used 
nonsteroidal anti-inflammatory drugs. Mean age was 61 years. 
characteristics did not differ between groups I and II. 
10.2.2 Laboratory procedures 
The following parameters, described in Chapter 2, were assessed. 
Erythrocyte parameters 
Hb, Ht, reticulocyte count. 
Iron status 
Ferritin. 
Disease activity 
ESR, CRP, Rose titer. 
Serum IL-6 
These 
Bone marrow aspirate (posterior superior iliac crest puncture) was 
stained for iron content. Twenty milliliter of aspirate was used for 
culturing erythroblasts. BFUe was used as parameter for erythropoiesis 
(Chapter 2.8.2). 
In 3 patients from group I, 8 from group II and in 5 normal donors 
IL-6 (1000 U/ml) and anti-IL-6 (1000 U/ffil) (Central Laboratory for the 
Blood Transfusion Service, Amsterdam, 
the BFUe cultures to evaluate 
The Netherlands) were added to 
their effects on in vitro 
erythropoiesis. In 7 patients (group I: 2, group II: 5) twice the 
amount of IL-6 and anti-IL-6 was added. 
10.3 RESULTS 
10.3.1 Parameters of erythropoiesis, disease activity and IL-6 in RA 
patients with and without ACD 
BFUe count was significantly lower in group II compared to group 
I (Table 1). Reticulocytes did not differ between the 2 groups. 
TABLE I E'Jthrocyte parameters, parameters of disease activity, IL-6 and Burst Forming Units (BFUe) per 
I cells in RA patients without anemia and ACD. 
Hb Ht Retics BFUe ESR CRP Rose 
mmol/1 1/1 0/00 col. per mm,lhr mg/1 reciprocal 
105 cells titer 
Nonanemic 7.9 0.39 17 260 34 8 32 
RA (n=9) (7.5-8.3) (0.35-0.42) (5-39) (215-391) (21-60) (4-45) (0-256) 
ACD 6.61 ) 0.311 ) 17 1912 ) 741 ) 622 ) 32 
RA (n=12) (5.4-7.3) (0.28-0.34) (1-28) (123-108) (40-105) (10-121) (0-256) 
Values are expressed as median with range. 1 > p<0.001, 2 > p<0.01, 3 > p<0.10. 
TABLE 2 Standard BFUe count (no addition; counts per 1rf' cells incubated) and 
Addition 
None 
IL-6 
Anti-IL-6 
absolute (abs) and relative (%) change in BFUe count after addition of 
IL-6 (1000 Ulml) and anti-IL-6 (1000 Ulml) to the cultures in controls, 
nonanemic and anemic RA patients. 
Controls (n=5) 
abs. % 
356 
(254-396) 
2661 ) 
(225-266) 
2192 ) 
(168-361) 
100 
80+201 ) 
(57-105) 
72+163 ) 
(55-92) 
Non-anemic/RA (n=3) 
abs. % 
246 
(242-282) 
294 
(168-318) 
2281 ) 
(180-244) 
100 
111+21 ) 
(109-113) 
86+101 ) 
(74-99) 
ACD/RA (n=8) 
abs. % 
173 
(12-440) 
155 
(6-471) 
1351 ) 
(8-329) 
100 
91+21 
(83-107) 
72+133 ) 
(43-83) 
Values expressed as median with range (percentages as mean and standard 
deviation). 
1
> p<0.10, 2 > p<0.05, 3 > p<0.01; compared to standard BFUe count. 
IL-6 Ferritin 
(,ug/1) 
0 39 
(0-11) (12-86) 
293 ) 1082 ) 
(0-82) (39-410) 
...... 
w 
0 
I 
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ESR and CRP were significantly higher in group II. Hb correlated 
negatively with ESR (r=-0.71; p<0.001) and CRP (r=-0.68; p<0.005). 
BFUe count correlated negatively with ESR (r=-0.65; p<0.005) and CRP 
(r=-0.66; p<0.01). No differences in Rose titer were found. 
Serum IL-6 tended to be higher in group II. IL-6 correlated 
positively with ESR (r=0.46; p<0.025) and CRP (r=0.52; p<0.025) and 
negatively with Hb (r=-0.41; p<0.05) but not with BFUe. 
10.3.2 Effects of addition of IL-6 and anti-IL-6 to bone marrow 
cultures (Table 2) 
BFUe count was higher in controls compared to ACD patients 
(p<0.05). The difference between controls (healthy donors) and 
nonanemics was not significant. 
IL-6 addition slightly inhibited BFUe count in controls but 
stimulated growth in nonanemics. In 7 cultures twice the amount of 
IL-6 was added (2 controls, 5 ACD; not shown). Mean percentual BFUe 
count was 109 ~ 18% compared to control BFUe count. 
Anti-IL-6 addition inhibited BFUe count in all groups, most 
pronounced in controls and ACD. Doubling the amount of anti-IL-6 added 
had no further inhibitory effect on BFUe count (mean 82 ~ 16%; p<0.01; 
not shown). 
10.4 DISCUSSION 
In this study we examined a potential pathogenetic role of IL-6 in 
ACD. 
Erythroid colony growth, measured by BFUe count, was impaired in 
patients with RA and ACD and not in nonanemic RA patients. 
Reticulocyte count was the same in nonanemic and anemic RA patients, 
which further points to an inadequate bone marrow response to the 
anemia. An inverse correlation was found between parameters of RA 
activity, i.e., ESR and CRP and BFUe count and Hb. These findings do 
not differ from those found in Chapter 9, which is not surprising 
since a randomly assigned subset of patients from Chapter 9 was 
examined here. In Chapter 9 we found that serum TNF~ correlated 
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positively with ESR and CRP. It inhibited, whereas anti-TNFtt 
stimulated, in vitro erythropoiesis, from which it was concluded that 
TNFtt might be an important factor in the pathogenesis of ACD in active 
RA. In iron deficient RA patients decreased iron availability was 
another pathogenetical factor. In this study we excluded iron 
deficient RA patients. 
IL-6 is a monokine with biological activities related to 
inflammatory responses [2,3]. It was shown that IL-6 levels were 
evaluated in serum and synovial fluid of patients with active RA 
[4,5]. 
Here we found that serum IL-6 levels correlated positively with 
parameters of RA activity, i.e. ESR and CRP, which confirms its role 
in the inflammatory response in RA. Serum IL-6 correlated negatively 
with Hb and it was elevated in most of our ACD patients. Since we 
found an inverse relationship between RA disease activity and BFUe 
count, it was assumed that IL-6, as TNFtt (Chapter 9) might be a 
mediator of impaired erythroid colony growth. 
IL-6 and anti-IL-6 antibodies were added to the bone marrow 
cultures in order to establish the effects on erythroid colony growth. 
IL-6 addition resulted in a slight inhibition of BFUe growth in 
controls and ACD. In nonanemic controls in contrast it stimulated 
erythroid growth. After addition of anti-IL-6 antibody erythroid 
colony growth was impaired in all cases. Addition of twice the amount 
of IL-6 or anti-IL-6 did not increase the in vitro effects of either 
two. From the data it is concluded that anti-IL-6 has inhibitory 
effects on erythroid colony growth. Probably IL-6 is produced by bone 
marrow monocytes in culture. Possibly the stimulatory effects of 
locally produced IL-6 might be neutralized by the addition of 
anti-IL-6 while IL-6 addition in the amount used here has no further 
effects on erythroid growth. The anti-IL-6 antibody specificity is not 
entirely known. So although a consistent inhibition of erythropoiesis 
occurred it is not known whether antibodies with a similar isotype 
might have caused the same suppression. It is for instance possible 
that it inhibits effects of other cytokines as well. IL-6 production 
is enhanced by IL-l and TNFtt [7,8,9]. It is therefore possible that 
IL-6 production in the marrow cultures is stimulated by IL-l and TNFtt 
production in the medium. These cytokines possess inhibitory effects 
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on erythropoiesis [10] (Chapter 9). In this way the potential 
stimulatory effects of IL-6 are masked in vitro. It might also be 
speculated that IL-6 triggers TNF~ and IL-l production resulting in 
nutralizing IL-6 effects as well. This might explain the inconsistent 
effects of IL-6 addition in the different groups. IL-6 has been found 
to trigger primitive hematopoietic cells into cell cycle in vitro, 
most pronounced in the presence of IL-3 [6], whereas others found that 
IL-6 had no effects on erythroid growth in acute myeloblastic leukemia 
[11]. Based on these preliminary data it seems unlikely that IL-6 
-shown to be raised in ACD- is a cause of ACD in RA. In contrast, it 
might be speculated, based on the findings of anti-IL-6 addition, that 
IL-6 might counteract suppressive effects of other interleukins such 
as IL-l [10] and TNF~ (Chapter 9) on erythroid colony growth. 
In summary, we found that serum IL-6 tended to be higher in ACD 
compared to nonanemics. It correlated positively with parameters of 
disease activity and negatively with Hb, suggesting a possible 
pathogenetical role in ACD. The effects of IL-6 addition to bone 
marrow cultures were inconsistent whereas anti-IL-6 addition . resulted 
in decreased erythroid colony growth. From these preliminary data it 
was concluded that IL-6 plays no pathogenetical role in ACD; it might 
be speculated that it even counteracts suppressive effects of other 
interleukins like IL-l and TNF~ on erythroid growth. 

CHAPTER 11 
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GEM:RAL DISCUSSI(XIl AND SUMMARY 
In Chapter 1 the various causes of anemia in RA as well as the 
factors associated with ACD were discussed. It is clear that many 
causes must be excluded before the diagnosis ACD in RA can be made.In 
the discussion of factors like iron absorption, the role of the MPS, 
ineffective erythropoiesis and Epo it became clear that many of these 
studies lack proper description of the patients iron status. Factors 
like ineffective erythropoiesis and the iron retention by the MPS were 
first associated with ACD but later also with iron deficiency. In a 
number of studies on the role of EpO iron deficient patients were not 
sufficiently separated from ACD making interpretation of the results 
difficult. A number of mediators of erythropoiesis were discussed. 
Their effects on erythropoiesis are not consistent while only a few of 
them were specifically studied in ACD in RA. This thesis was performed 
to assess reliable methods to classify anemic RA patients which is 
inevitable for studies concerning pathogenesis of ACD. The other 
objective was to study the specific role in ACD of iron availability 
to erythroblasts and the effects of Epo, TNFa and IL-6 on (in vitro) 
erythropoiesis. 
In Chapter 2 the various laboratory procedures as well as the 
statistical methods were described. 
1/.1 Diagnostic and therapeutic aspects of the anemia in RA (Chapter 
3, 4 and 5) 
In all studies presented here patients classification was based on 
stainable bone marrow iron content (1,2) in order to discriminate iron 
deficient patients from those having ACD. In combination with serum 
vitamin B12 and folic acid determinations it was shown that only 24% 
of RA patients have just one cause of anemia (ACD) while other 
subjects had combinations. If one relies on cellular indices only (MCV 
and MCH) many patients would have been classified as having ACD while 
in fact often a combination of iron and vitamin B12 or folic acid 
deficiency is present which has important diagnostic (workup for 
analysis of these deficiencies) and therapeutical consequences. 
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If all other causes of anemia are excluded the problem remains to 
detect iron deficiency if one wishes to avoid bone marrow examinations 
in all anemic RA patients. We found that MCV is the most specific and 
predictive parameter for the detection of iron deficiency. Ferritin is 
the most valid serum assay in this respect. Since ferritin is an acute 
phase reactant (3), clearly confirmed here because of a positive 
correlation with ESR and CRP, its lower reference limit must be 
elevated (from 14 to 50 pg/1) for the purpose of detection of iron 
deficiency. Ferritin level in iron deficiency is similar as in 
nonanemic patients for the same reasons since in iron deficiency RA 
activity was higher than in nonanemics. Serum transferrin (as TIBC) 
was even lower in iron deficiency than in nonanemics which is 
contradictory to what is found in uncomplicated iron deficiency (4) 
while ACD was found to be associated with a low serum transferrin and 
iron saturation. This shows that iron deficient patients also have 
features of ACD which is associated with the highest level of RA 
activity. This assumption was further confirmed by the finding that 
iron treatment of iron deficient RA patients results in only a limited 
Hb increase. RA activity, associated with ACD, probably determines 
maximal HB rise. In ACD patients no Hb rise occurred. ·The iron 
administered does not result in increased iron availability to 
erythroblasts and increased erythropoiesis possibly due to iron 
retention by the MPS or other pathogenetical factors. MCV and ferritin 
are reliable serum parameters to predict a Hb rise. The combination of 
the serum parameters MCV, transferrin and ferritin at their respective 
cut off points results in a 100% valid assessment of iron stores in RA 
patients while the combination of MCV and ferritin predicts iron 
responsiveness of the anemia in RA in 100% of cases. 
It is concluded that anemia in RA has a multifactorial cause and 
complete evaluation is necessary for diagnostic and therapeutic 
consequences. Bone marrow aspiration is rarely necessary. In Fig.1a 
and 1b the approach of the anemic RA patients is shown schematically. 
11.2 Pathogenetic aspects of ACD in RA 
Impaired iron absorption -once thought to be of pathogenetical 
value in ACD [5]- was found to be lower in ACD using a simple iron 
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Figure !A Causes of anemia in RA 
Figure IB Predicition of iron deficiency in anemic RA patients using 
MCV and serum ferritin as key parameters 
ferritin <50 JlQIL 
(11/11 (100%) iron.def.) 
ferritin ~50 JlQIL 
(2/ 4 (50%) iron.def.) 
ferritin <50 pJJ/L 
(6/10 (60%) iron.def.l 
ferritin ~50 pJJIL 
(4/19 (21%) iron.def.l 
def. = deficiency, ACD = anemia of chronic disease, Bl2 = vitamin Bl2, 
FH4 = folic acid 
(Percentages reflect the number of patients within the subgroup). 
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absorption test [6] (Chapter 4,5). In ACD iron stores are normal to 
elevated (measured as ferritin and stainable bone marrow iron) so a 
decreased iron absorption can not be the cause of ACD. Moreover, iron 
absorption was significantly higher in subjects without stainable 
iron. Therefore impaired iron absorption is rather the result of 
active RA and possibly a compensation to increased iron stores. 
The increased iron stores found in ACD apparently are not available 
to bone marrow. Even treatment with iron does not result in increased 
erythropoiesis (Chapter 5). We therefore examined whether iron uptake 
or transferrin binding by erythroblasts could be impaired in ACD 
(Chapter 6). Indeed we observed that iron incorporation was reduced in 
ACD compared to nonanemics and healthy controls in ACD. Iron 
incorporation correlated negatively with CRP, an RA disease parameter, 
explaining the relatively small difference with iron deficient RA 
patients in which RA activity was approximately the same as in ACD in 
this subset of patients. The impaired iron uptake by erythroblasts 
might be caused by a significant decrease in transferrin binding to 
erythroblasts in ACD although considerable overlap occurred with the 
other RA groups. The findings confirm that iron availability to 
erythroblasts is reduced in ACD. It is not certain whether the 
phenomenon of reduced iron uptake and transferrin binding by 
erythroblasts is primary, i.e. causing the anemia, or secondary due to 
other factors involved in ACD pathogenesis like iron retention by the 
MPS [7] or hematopoietic growth factors discussed below. 
We studied the role of Epo, and the cytokines TNF~ and IL-6 in the 
pathogenesis of ACD in RA (Chapter 7,9,10). It was shown that serum 
Epo was increased in all RA patients compared to healthy controls 
using two different tests. Apparently in nonanemic RA patients this 
response is sufficient to prevent anemia. In part one of Chapter 7 a 
negative correlation between Hb and Epo was present most clearly in 
iron deficient patients. In part two of Chapter 7 this was not found. 
In ACD obviously no clear correlation exists between Hb and Epo 
confirming the insufficent response to the anemia in ACD. 
Another finding was a higher serum Epo in iron deficient RA 
patients compared to subjects with ACD while Epo level correlated 
negatively with ferritin in nonanemic patients. It was concluded that, 
beside RA disease activity (generally highest in ACD), increased iron 
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stores could inhibit Epo response to the anemia. A group of 10 RA 
patients with ACD therefore were treated with the oral iron chelator 
Ll to examine whether release of iron from iron stores results in 
increased Hb and serum Epo (Chapter 8). Iron was effectively chelated 
as shown by the rise in serum and urine iron, a rise in iron 
saturation of transferrin and a decrease of ferritin after 1 week of 
treatment. Both Hb and Epo tended to rise after 1 week treatment and a 
positive correlation was found between Hb and Epo change whereas 
changes in both parameters correlated negatively with ferritin 
changes. This suggests that Epo response to ACD may increase following 
iron release from iron stores and that it might cause a Hb rise 
although the findings are preliminary. It might also be that through 
increased iron exchange from transferrin to ferritin iron availability 
for erythroblasts increases, resulting in a Hb rise. Since it is 
postulated that transferrin expression increases following chelation 
therapy [8] it could be argued that iron incorporation into 
erythroblasts, shown to be impaired in ACD (Chapter 6), increases 
after Ll treatment. 
BFUe colony counts were found to be reduced in ACD suggesting that 
the anemia has its basis at stem cell level (Chapter 9). This is 
probably indirectly mediated by increased RA activity. It is not known 
whether in ACD the erythroblasts become less sensitive to Epo which is 
added to BFUe mediums. If so, not only Epo responsiveness to the 
anemia is impaired but also Epo sensitivity of erythroblasts although 
of course other intrinsic erythroblast or medium factors could be 
involved. The low number of BFUe counts found in iron deficiency might 
be explained by low iron stores, available for erythroblast growth as 
well as RA disease activity. 
We studied TNFa and IL-6 as pos&ible mediators of impaired 
erythropoiesis in order to find a mechanism through which RA activity 
determines the anemia. Both hematopoietic growth factors probably play 
a pathogenetic role in RA [9,10]. Both serum TNFa and IL-6 correlated 
positively with parameters of RA activity like ESR and CRP. We 
investigated their effects on BFUe growth. TNFawas found to inhibit 
erythropoiesis in vitro whereas anti-TNFa resulted in a stimulation of 
erythropoiesis (Chapter 9). IL-6 in contrast had no consistent effects 
on erythropoiesis while anti-IL-6 exerted an inhibitory effect on BFUe 
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counts (Chapter 10). It was concluded that TNF~, its serum level being 
associated with RA activity is an important factor in ACD pathogenesis 
whereas IL-6 is not. Based on the findings of anti-IL-6 addition, IL-6 
produced by monocytes in the medium might stimulate erythropoiesis and 
in this way counteract the effects of TNF~. It is obvious that in 
marrow cultures TNF~ and IL-6 production takes place in vitro which 
complicates extrapolation of the findings to the in vivo situation. 
In Table 1 study objectives of and results obtained by our 
investigations are shown. 
TABLE I Study objectives of and results obtained by this thesis 
STUDY OBJECTIVES 
- Frequency of iron, Bl2 and 
folic acid deficiency in 
anemic RA patients. 
- Effects of these deficiencies 
on diagnostic parameters. 
- Characterization of blood 
parameters in ACD with and 
without iron deficiency. 
- Indication of bone marrow 
aspiration. 
- Prediction of iron 
responsiveness of the 
anemia. 
- Increase of RA activity 
after iron treatment. 
- Role of impaired iron 
uptake and transferrin 
binding by erythroblasts. 
RESULTS OBTAINED 
- 52%, 29% and 21% respectively. 
- Just one cause of anemia in 
only 24% of patients. 
- Normal values of cellular 
indices may mask combined 
deficiencies. 
- Reliable prediction of iron 
deficiency after adaption 
of reference values of MCV, 
ferritin and transferrin. 
- Bone marrow aspiration 
rarely indicated. 
- Accurately, by means of MCV 
and serum ferritin after 
adapting their reference 
values. 
- No apparent serological 
effects. 
- Iron incorporation and 
transferrin binding 
decreased in ACD. 
- Transferrin binding reduced 
in all RA patients. (Only 
significantly in ACD. 
- Overlap with iron 
deficiency due to RA 
activity 'levels comparable 
to ACD? 
5 - Decreased Epo response to 
the anemia. 
6 - Effects of iron chelation 
on erythtopoiesis and Epo 
responsiveness 
7 - The role of TNF-alpha in ACD 
8 - The role of IL-6 in ACD 
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- Epo levels higher in RA 
patients compared to 
healthy controls. 
- Response insufficient to 
prevent anemia in ACD .. 
- Possible negative 
correlation of serum Epo 
with iron stores. 
- Hb and serum Epo rise 
- Possible correlation 
between Hb and Epo change. 
- Negative correlation of Hb 
and serum Epo change with 
ferritin change .. 
- BFUe numbers reduced in ACD 
- Increased serum TNF-alpha in ACD 
correlated with RA activity 
- Suppressive effects of TNF-alpha 
on in vitro erythropoiesis .. 
- Stimulation of in vitro erythro-
poiesis by anti-TNF-alpha addition 
addition. 
- Increased serum IL-6 levels in ACO. 
- Positive correlation with RA 
activity. 
- Possible stimulatory effects on in 
vitro erythropoiesis .. 
- Inhibitory effects of anti -IL-6 on 
in vitro erythropoiesis. 
In conclusion, the present work shows that many potential treatable 
causes are present simultaneously in RA complicated by ACD. The 
finding of normal cellular indices may mask combined deficiencies 
whereas the presence of iron deficiency can be detected generally 
without performing a bone marrow aspiration for stainable iron 
assessment. Iron treatment is useful only in iron deficient RA 
patients and its response can easily be predicted by blood parameters. 
The findings suggest that impaired erythropoiesis in ACD may be due 
to reduced iron uptake and transferrin binding by erythroblasts while 
Epo response to the anemia is decreased as well. Oral iron chelation 
by Ll might increase Hb through increased bone marrow iron 
availability or through a rise in Epo responsiveness after iron 
release from the MPS. TNF~, correlated with RA activity, might mediate 
impaired erythropoiesis while IL-6, correlated with RA activity as 
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well, might counteract the effects of TNF~. 
It seems logical to assume that the factors associated with ACD 
studied here might interact with each other. Further studies are 
required to establish these interactions. In Figure 2 an effort is 
made to speculate on possible interrelationships. 
FIGURE 2 Possible interactions of pathogenetical factors in ACD 
Fig.2 Possible interactions of pathogenetical factors in ACD 
G ~ Stimulation 
() ~ Inhibition 
? =Speculative/questionable 
EPO = Erythropoietin 
TNFa =Tumor necrosis factor a 
IL6 ~ lnterleukin 6 
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SMENVATTING 
In hoofstuk 1 werden de vele oorzaken van anemie bij RA alsrnede de 
factoren geassocieerd met ACD beschreven. De diagnose ACD kan slechts 
per exclusionem gesteld worden. In veel van de beschreven studies 
bestaat er een onvoldoende classificatie van de ijzerstatus van de RA 
patienten zodat bevindingen die in eerste instantie pasten bij ACD 
later ook bij ijzerdeficientie bleken voor te komen. Diverse 
mediatoren van erythropoiese werden besproken, doch deze stoffen zijn 
slechts in beperkte mate onderzocht als pathogenetische factor bij 
ACD. 
De hoofddoelstellingen van dit proefschrift waren enerzijds het 
vaststellen van een betrouwbare methode om anernische RA patienten te 
classificeren en anderzijds het nagaan of verrninderde ijzerbeschik-
baarheid voor erythroblasten, verrninderde Epo respons op de anemie, en 
de effecten van TNFa en IL-6 op de (in vitro) erythropoiese een rol 
spelen in de pathogenese van ACD. 
In hoofdstuk 2 werden de hernatologische en klinisch chernische 
bepalingen en de methoden met betrekking tot de in vitro experimenten 
met erythroblasten alsmede de statistische methoden beschreven. 
In hoofdstuk 3 werd aangetoond dat slechts 24% van de anernische 
patienten een oorzaak van anernie hebben (ACD). De overigen hebben 
combinaties van deficienties (ijzer, B12 en foliurnzuur) en ACD die 
gernaskeerd kunnen worden door het vinden van norrnale indices. 
In hoofdstuk 4 werd verder ingegaan op de ijzerstatus van de RA 
patienten die in 52% van de gevallen ijzerdeficient bleken te zijn. 
Indien de referentiewaarden van MCV, ferritine en transferrine 
enigzins aangepast worden, voorspellen zij nauwkeurig de aanwezigheid 
van ijzerdeficientie. Een beenrnergaspiratie voor kleurbaar ijzer is 
derhalve zelden geYndiceerd. 
In hoofdstuk 5 bleek dat dezelfde parameters, met name MCV en 
ferritine ook een Hb stijging na ijzerbehandeling nauwkeurig konden 
voorspellen. Alleen ijzerdeficiente RA patienten hadden een Hb 
stijging. Blijkbaar leidt het toedienen van extra ijzer niet tot 
verhoogde ijzerbeschikbaarheid voor het beenrnerg bij ACD patienten. 
Deze verrninderde ijzerbeschikbaarheid is verder onderzocht in 
hoofdstuk 6. Bij RA patienten met ACD werd een evident verrninderde 
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ijzerincorporatie in de erythroblasten gevonden die correleerde met de 
RA activiteit. Bij ACD is de transferrine binding aan de erythroblast 
ook verminderd hetgeen de lagere ijzerincorporatie verklaart, hoewel 
er overlap was met de ijzerdeficiente groep waarschijnlijk als gevolg 
van overlap in RA activiteit. Het lijkt dat verminderd ijzertransport 
naar de erythroblast een rol zou kunnen spelen als pathogenetische 
factor bij ACD. 
In hoofdstuk 7 deel 1 en 2 werd beschreven dat serum Epo spiegels 
hoger zijn in alle RA groepen in vergelijking met controles. Bij ACD 
lijkt de Epo respons iets minder dan bij ijzerdeficientie en is dus 
onvoldoende om het Hb-niveau te handhaven. Er werd een negatieve 
correlatie tussen ferritine -als maat voor de ijzervoorraad- en serum 
Epo gevonden. 
Dit mogelijk negatieve verband werd vervolgens in hoofdstuk 8 
verder nagegaan door 10 RA patienten met ACD te behandelen met de 
orale ijzerchelator Ll. Het ijzer werd effectief uit de ijzervoorraad 
gecheleerd en een Hb en Epo stijging werd gevonden waarbij de Hb en 
Epo veranderingen positief correleerden. Bovendien correleerden de Hb 
en Epo veranderingen negatief met ferritine veranderingen. Het lijkt 
derhalve mogelijk dat de Epo respons bij ACD toeneemt na ijzerafgifte 
van het MPS. De Hb stijging zou dus verklaard kunnen worden door de 
toegenomen Epo respons of door een verhoogde ijzerbeschikbaarheid voor 
erythroblasten door ijzeruitwisseling tussen transferrine en 
ferritine. De resultaten zijn echter preliminair. 
Hoofdstuk 9 en 10 beoordelen de rol van de cytokines TNF~ en IL-6 
bij ACD. In vitro bleek de erythro~de groei (aantal BFUe kolonies) 
geremd te zijn. Ook bij ijzerdeficientie bleek dit het geval te zijn, 
hetgeen verklaard werd door verminderde ijzervoorraden beschikbaar 
voor erythroblasten, en ziekteaktiviteit. Gezien de positieve 
correlatie van serum TNF~ en IL-6 met RA ontstekingsparameters alsmede 
het feit dat de spiegels het hoogst waren in de ACD groep werden de 
effecten van deze cytokines op de erythro~de groei in vitro 
onderzocht. TNF~ bleek suppressie te geven van de erythro~de groei 
terwijl anti-TNF~ stimulatie gaf. IL-6 had inconsistente effecten op 
het aantal BFUe kolonies en anti-IL-6 gaf inhibitie. Het zou dus 
mogelijk kunnen zijn dat TNF~, verhoogd bij actieve RA, een oorzaak is 
van ACD terwijl IL-6, gezien de negatieve effecten van anti-IL-6, 
- 148-
juist deze remming tegengaat. waarschijnlijk is er veel TNF~ en IL-6 
productie in het mediumwaardoor bijvoorbeeld de stimulerende effecten 
van IL-6 gemaskeerd werden. Diezelfde in vitro cytokine productie 
maakt extrapolatie van de in vitro effecten naar de in vivo situatie 
echter moeilijk. 
In Figuur 2 van hoofdstuk 11 wordt een schema voorgesteld voor 
de mogelijke samenhang van de diverse pathogenetische factoren met 
betrekking tot ACD zeals in dit proefschrift bestudeerd. 
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